Systems Biology Framework Unravels Molecular Substrates Underlying Comorbidity Between Parkinson's and Crohn's Disease

Yanshi Hu, Bentao She, Zhounan Yin, Xinjian Yu, Wenyi Wu, and Ming Chen**

Yanshi Hu, Bentao She, Zhounan Yin, Xinjian Yu, Wenyi Wu, Ming Chen
Department of Bioinformatics, College of Life Sciences, Zhejiang University, Hangzhou 310058, China
E-mail: yanshihu@zju.edu.cn, Yanshi Hu; mchen@zju.edu.cn, Ming Chen

Xinjian Yu
Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital and Cancer Center, Houston, TX, USA.

Ming Chen
Zhejiang Key Laboratory of Multi-omics Precision Diagnosis and Treatment of Liver Diseases, Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, 310016, Hangzhou, China
E-mail: mchen@zju.edu.cn, Ming Chen

Ming Chen
Biomedical Big Data Center, The First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Hematology, Zhejiang University, Hangzhou 310058, China
E-mail: mchen@zju.edu.cn, Ming Chen

Funding: National Key Research and Development Program of China (2023YFE0112300), National Natural Sciences Foundation of China (32261133526; 32270709; 32070677), the 151 talent project of Zhejiang Province (first level), the Science and Technology Innovation Leading Scientist (2022R52035).

Keywords: Parkinson's disease, Crohn's disease, systems biology, comorbidity

Abstract

In an era of global aging, the escalating burden of chronic disease comorbidity presents a major clinical challenge, making it imperative to decipher the molecular underpinnings of such links to advance diagnostics and therapies. The mechanistic basis for the comorbidity between Parkinson's and Crohn's disease, in particular, remains obscure. Systems biology framework in the current study deciphers this enigmatic nexus by integrating genetic architecture with tissue-specific functional genomics and pathway network. A significant shared genetic landscape is established, converging on host-pathogen interactions and barrier integrity. Translating this to a functional context reveals profound transcriptional synergy, wherein the blood milieu in Crohn's disease is highly aligned with the substantia nigra pathological state of Parkinson's disease. The physical conduit for this aberrant crosstalk is identified as a sequential breach of the gut epithelial, gut-vascular, and blood-brain barriers. These findings culminate in a cohesive "gut-blood-brain axis" model, positing a directional cascade where peripheral inflammation in Crohn's disease directly facilitates central nervous system degeneration. This work reframes the etiology of Parkinson's disease, positioning peripheral inflammatory triggers as direct contributors to neurodegeneration and offering a new paradigm for therapeutic intervention.

1. Introduction

As one of the devastating neurodegenerative diseases, Parkinson's disease is characterized by both progressive motor and non-motor symptoms which affect daily life, and is reported by The Global Burden of Disease study to have the fastest increase in global prevalence and mortality among neurological diseases.[1] In 2016, there are about 6.1 million Parkinson's patients in aged populations worldwide[2] and the number is anticipated to be double by 2040,[3] which exerts a critical mental and financial burden on caregivers and societies. Parkinson's disease results in more than 340,000 deaths per year around the globe and the mortality has been ever soaring with 38.3% increase during ten years from 2007 to 2017.[4] Though how Parkinson's disease occurs and evolves remains elusive, mounting evidence indicates vital roles of genetics in its sporadic form.[5-6] Despite substantial paradigm shift[7] and ever-lasting translational and clinical efforts, to date there are still no efficacious disease-attenuating drugs and therapies for patients with Parkinson's disease.[8] Thus, decoding underlying mechanisms driving Parkinson's disease is an urgent unmet need for pharmaceutical development and disease curation.

Crohn's disease, a chronic type of inflammatory bowel disease (IBD), often occurring in the ileocolic and/or colonic part(s) of the intestine,[9] accompanied by a morbidity about 30 cases out of 100,000 people one year.[10] For the United States only, there are more than 700,000 Crohn's patients.[11] It is widely accepted that the pathogenesis of Crohn's disease is comprised of genetic, microbiomic, and other environmental elements.[9, 12] Genome-wide association studies (GWAS) have contributed to the identification of more than 200 markedly predispositional Crohn's disease genetic sites.[13] However, these well-established loci could only account for approximately 13% of Crohn's morbidity,[12] which indicates a wide gap between current state of the art and definitive underpinnings of Crohn's disease.

It has been acknowledged early Parkinson's patients are at increasing risk to have bowel symptoms, e.g., constipation.[14] Growing knowledge has led to the hypothesis that chronic intestinal inflammation or IBD might elicit Parkinson's disease etiology.[15-16] While controversies on the impact of Crohn's disease on Parkinson's disease exist,[17-19] more and more genetic,[20-23] epidemiological, and biochemical studies[24] have strengthened the connections between Parkinson's and Crohn's disease in various populations, incl. Taiwanese,[25] Swedes,[26] Danes,[27] Americans,[28] and South Koreans.[29] As a result, IBD treatment might be able to ameliorate the susceptibility or postpone the onset of Parkinson's

disease.[28, 30] Although multiple efforts have been made, insights into the systemic pairwise relation between Parkinson's and Crohn's disease are still lacking,[31] and investigations on elucidating causal relationship between Parkinson's and Crohn's disease from a holistic perspective, may pave a brand-new way for mechanistic decryption.

This enigmatic comorbidity is deciphered herein through a systems biology framework that bridges the genetic landscape with tissue-specific functional genomics and pathway network. We begin by curating and dissecting the shared genetic architecture of Parkinson's and Crohn's disease, revealing a profound, non-random overlap that converges on host-pathogen interactions and barrier integrity. We then systematically interrogate the transcriptional activity of these genetic pathways across five disease-relevant tissues—the ileal and colonic mucosa, blood, and substantia nigra—uncovering remarkable intra- and cross-tissue synergy and a strong transcriptional alignment between the systemic milieu of Crohn's disease and the substantia nigra pathology of Parkinson's disease. Building on this, we provide a tangible physical basis for this crosstalk by demonstrating a sequential breach of the gut epithelial, gut-vascular, and blood-brain barriers. Our findings culminate in a cohesive gut-blood-brain axis model for Parkinson's and Crohn's disease comorbidity, which posits a directional pathogenic cascade initiated by intestinal pathology in Crohn's disease that directly promotes neurodegeneration in Parkinson's disease. This work not only provides a comprehensive, data-driven framework for the comorbidity but also reframes the etiology of Parkinson's disease, positioning peripheral inflammatory triggers as direct contributors to central nervous system pathology.

2. Results

2.1. A shared genetic landscape underpins Parkinson's and Crohn's disease

Following a stringent processing strategy (**Figure 1**a and "*Genetic association data curation*" in Experimental Section), our keyword-based search on PubMed initially yielded 4,411 and 3,137 publications for Parkinson's and Crohn's disease, respectively. A meticulous literature filtration process subsequently narrowed this corpus to 677 and 318 publications with genuine relevance to genetic variants in Parkinson's and Crohn's disease. Finally, a comprehensive full-text review allowed us to curate a high-confidence dataset comprising 747 genetic variants in 313 genes for Parkinson's disease, and 623 variants in 319 genes for Crohn's disease (Figure 1b; Table S1 and S2, Supporting Information).

A comparative analysis of these datasets revealed a significant genetic intersection, with 26 variants and 31 genes shared between Parkinson's and Crohn's disease (Figure 1c). Intriguingly, 16 of these 31 shared genes were exclusively linked to disease-specific variants. This finding points toward a compelling comorbid mechanism wherein distinct genetic perturbations converge upon a common set of genes, thereby orchestrating shared downstream pathological events. Among these shared genes, MMP9[32] and ABCB1[33] are known to modulate blood-brain barrier permeability, providing a potential conduit for Crohn's peripheral pathologies to influence central nervous system processes in Parkinson's disease. The presence of PGLYRP4, a peptidoglycan recognition protein,[34] hints at a shared role for bacterial sensing and immune response in both disorders. Angiotensin-converting enzyme (ACE) links the shared genetic risk to dysregulated blood pressure, a non-motor feature associated with Parkinson's pathology.[35] The inflammasome component NLRP3,[36-37] along with downstream NF-κB signaling cascade,[38-39] points to a shared inflammatory axis, which is pathologically active in Parkinson's and Crohn's disease. Mutations of LRRK2—a multi-domain protein—confer significant risk for both conditions.[40-41] Collectively, these findings establish a substantive genetic nexus between Parkinson's and Crohn's disease.

To ascertain that the observed genetic overlap was statistically significant and not a product of random chance, we employed a Monte Carlo simulation approach with 100,000 iterations to calculate empirical *P*-values. The simulation robustly confirmed the profound statistical significance of the overlap for both the genetic variants and their associated genes ($P < 10^{-5}$ for both), underscoring the authenticity of this shared genetic architecture (Figure 1d, e).

We further delved into the genomic distribution and functional annotation of the variant datasets, which revealed strikingly similar patterns between the two diseases (Figure S1a, b, Supporting Information). Variants for both were distributed across the autosomes. However, several key distinctions emerged. Notably, Crohn's variants were identified on the Y chromosome while Parkinson's variants were not, an observation that aligns perfectly with recent reports negating a strong link between Parkinson's disease and the Y chromosome.[42] Conversely, mitochondrial variants were unique to Parkinson's disease (Figure S1c, Supporting Information), suggesting that mitochondrial dysfunction, while a hallmark of Parkinson's disease, may not be a primary genetic driver in Crohn's disease. The pathogenic contribution of mitochondrial variants in Parkinson's disease does not appear to be dominated

by any single functional class. Instead, synonymous, missense and unannotated variants are present in commensurate frequencies and uniformly scattered across the mitochondrial genome, raising the possibility that all three types contribute significantly to the disease's genetic risk. A comparison of variant functional annotations further solidified this disease similarity, with variants predominantly located in intronic regions, followed by missense and unannotated variants (Figure 1f). This highlights that the functional consequences of many variants implicated in Parkinson's and Crohn's comorbidity remain to be elucidated.

Expanding our analysis to the gene level, we observed a continued trend of functional similarity. In both diseases, over 90% of the genetically-implicated genes were protein-coding (Figure 1g). This starkly contrasts with the vastness of the non-coding genome, highlighting a significant knowledge gap and potential bias in current genetic studies. To address this deficit, we leveraged variant annotations from the dbSNP database to predict novel disease-related genes, successfully identifying 110 and 50 potential candidates for Parkinson's and Crohn's disease, respectively (Table S3 and S4, Supporting Information). The credibility of these predictions was substantiated through both extensive literature mining and quantitative evidence from our recently proposed transcriptomic meta-analysis method, AWmeta[43] ("*Transcriptomic meta-analysis of Parkinson's and Crohn's disease*" in Experimental Section). An examination of these expanded gene sets revealed a dramatic shift: non-coding genes now constitute over 50% of the total in both diseases (Figure 1h). This effort effectively supplements the initial protein-coding-centric view, providing a more comprehensive and balanced genetic landscape for exploring the comorbidity between Parkinson's and Crohn's disease.

2.2. Variant-enriched disease pathways implicate Parkinson's and Crohn's disease comorbidity

Given that the Kyoto Encyclopedia of Genes and Genomes (KEGG)[44] provides a well-curated repository of biological pathways linked to human diseases, it serves as a powerful platform for investigating inter-disease connections at a functional enrichment level. We therefore performed a disease pathway enrichment analysis on the Parkinson's and Crohn's genetic variants ("*Bio-functional aggregation of genetic association data*" in Experimental Section). Our objective was to map the broader disease landscape associated with each disorder, thereby gaining novel perspectives on the mechanistic underpinnings of their comorbidity.

This enrichment analysis revealed that Parkinson's and Crohn's disease share 38 human disease pathways (Figure S2; Table S5 and S6, Supporting Information). Notably, these commonly enriched pathways consistently demonstrated greater statistical significance than the disease-specific pathways for either condition, suggesting they represent core pathological processes of central importance to both Parkinson's and Crohn's disease. As a critical internal validation of our gene sets, the top-enriched pathway for Parkinson's disease was "Parkinson disease" itself, with the three most significant hits all being neurodegenerative disorders; similarly, the premier hit for Crohn's disease was "Inflammatory bowel disease".

A striking asymmetry emerged from this analysis. While "Inflammatory bowel disease" ranked as the eighth most significant pathway for the Parkinson's genes, the reciprocal was not true: "Parkinson disease", or indeed any neuro-related pathway, was conspicuously absent from the Crohn's enrichment results. This non-reciprocal relationship strongly suggests a directional influence, where the genetic architecture of Parkinson's disease encompasses susceptibility to Inflammatory bowel disease-like processes, whereas the genetic basis of Crohn's disease does not inherently predispose to parkinsonism. This finding lends a strong genetic support to the clinical hypothesis that inflammatory processes originating in conditions like Crohn's disease can act as a catalyst for the initiation or progression of Parkinson's disease, while the reverse is not established.[45-46]

Further exploration of the shared pathways provided deeper mechanistic insights. The enrichment of "Lipid and atherosclerosis" and "Fluid shear stress and atherosclerosis" implicates dysregulated lipid metabolism as a common pathological feature.[47-48] Similarly, the shared enrichment of "Type I diabetes mellitus" and "Insulin resistance" points toward aberrant insulin signaling as a convergent metabolic vulnerability in both diseases.[49-50]

Intriguingly, an examination of the disease-specific pathways unveiled a potential etiological link. Pathways for "Hepatitis B" and "Hepatitis C" were uniquely enriched in the Crohn's gene set; concurrently, "Hepatocellular carcinoma" was a specific enrichment item for Parkinson's disease. Given that chronic viral hepatitis is a primary driver of hepatocellular carcinoma,[51] this constellation of findings hints at a possible pathogenic trajectory where systemic inflammation and hepatic stress associated with Crohn's genetic background may contribute to a cellular environment conducive to pathologies seen in Parkinson's disease.

2.3. Parkinson's and Crohn's genetic variants converge on host-pathogen interactions and barrier integrity

To obtain a panoramic view of the biological functions encoded by the shared genetic architecture of Parkinson's and Crohn's disease, we first conducted a broad-stroke Gene Ontology (GO) enrichment analysis using WebGestalt.[52] This revealed a remarkably congruent functional landscape for both diseases at a high level (**Figure 2**a). Within the Biological Process (GO-BP) category, terms such as "biological regulation", "response to stimulus", and "metabolic process" were top hits for both, implicating shared roles for regulatory homeostasis, environmental stress responses, and metabolism. Similarly, in the Molecular Function (GO-MF) and Cellular Component (GO-CC) domains, terms like "protein binding", "ion binding", and "membrane" were commonly enriched, highlighting the importance of molecular interactions at cellular membranes in the etiology of both disorders.

To achieve greater functional resolution, we performed a more detailed GO enrichment analysis ("*Bio-functional aggregation of genetic association data*" in Experimental Section). Examination of the top 40 shared significantly-enriched GO-BP terms unveiled a striking thematic convergence on pathogen recognition and host defense (Figure 2b; Table S7, Supporting Information). A substantial proportion of these terms, including "response to peptidoglycan", "lipopolysaccharide-mediated signaling pathway", and "detection of molecule of bacterial origin", strongly implicated host-pathogen interactions as a central element of the shared genetic risk. Two particularly compelling findings emerged from this analysis. First, the enrichment of "positive regulation of nitric-oxide biosynthetic process" was surprising, as nitric oxide is a potent modulator of blood-brain barrier integrity.[53] This finding provides a direct genetic link to potential blood-brain barrier dysfunction as a component of the comorbidity. Second, the enrichment of "maintenance of gastrointestinal epithelium" pointed directly to the intestinal epithelium's homeostasis as a shared biological vulnerability. The GO-MF and GO-CC results further substantiated the pathogen response theme (Figure 2c; Table S8–S11, Supporting Information), solidifying the hypothesis that processes governing the recognition of and resistance to pathogens and their derivatives play a pivotal role in the shared Parkinson's and Crohn's mechanism. We designated these potentially functional terms as "GO hotspots" (indicated by red asterisks in Figure 2).

To further determine if these genetically-defined GO hotspots were functionally active in disease-relevant tissues, we analyzed their transcriptional status across our five tissue datasets, i.e., the substantia nigra and blood in Parkinson's disease, and the ileal and colonic mucosa and blood in Crohn's disease (**Figure 3**; "*Transcriptomic GO and pathway enrichment of Parkinson's and Crohn's disease*" in Experimental Section). Remarkably, the pathogen recognition and resistance processes were significantly and broadly activated (Normalized Enrichment Score, NES > 0) across all five contexts. This system-wide activation signature strongly suggests a persistent state of heightened immune surveillance, likely driven by an elevated presence of pathogens or their molecular patterns in these tissues compared to healthy controls.

As expected, processes related to neuronal activity were globally downregulated (NES < 0) in the Parkinson's substantia nigra, reflecting its characteristic neurodegenerative pathology. These same processes showed no consistent dysregulation in the other four tissues, underscoring their tissue-specific nature. Notably, however, "positive regulation of neuron apoptotic process" was significantly upregulated across all three Crohn's tissues, revealing a potential, previously underappreciated pro-apoptotic systemic environment in Crohn's disease that could impact neuronal health. Furthermore, we observed a significant activation of the "positive regulation of Wnt signaling pathway" in both the ileal and colonic mucosa of Crohn's patients. Given that aberrant Wnt activation is a recognized hallmark of compromised intestinal barrier integrity and increased permeability,[54-55] this result provides direct transcriptomic evidence of a defective gut barrier in Crohn's disease, lending mechanistic support to the gut-origin hypothesis of the comorbidity.

Finally, to assess the relative importance of different biological processes at the genetic level, we compared the top 40 enriched GO-BP terms for each disease (Figure S3; Table S12 and S13, Supporting Information). This revealed that the shared functional space was almost exclusively dominated by immune-related processes, cementing the immune system's role as the central arena for the Parkinson's and Crohn's disease interaction. Moreover, for Crohn's disease, nearly all of its top 40 enriched terms were immune-related, confirming that immune dysregulation is the preeminent feature of its genetic etiology.

2.4. Genetically-informed genes and biological pathways exhibit coordinated transcriptional activities within and across tissues in Parkinson's and Crohn's disease

To translate the genetic findings into a functional context, we next determined the biological pathways enriched within the Parkinson's and Crohn's variants ("*Bio-functional aggregation of genetic association data*" in Experimental Section). This investigation uncovered 18 shared pathways whose enrichment consistently reached a higher statistical significance than pathways specific to either disease alone, underscoring their central importance to the shared pathophysiology (**Figure 4**a; Table S14 and S15, Supporting Information). Among these, the co-enrichments of the "IL-17 signaling pathway" and "Th17 cell differentiation" resonate with our GO findings, as hyperactive Th17 cells are potent producers of the cytokine IL-17, a key mediator of antimicrobial peptide production,[56] thus reinforcing the theme of host-pathogen interactions. Intriguingly, the "Intestinal immune network for IgA production" was also a shared pathway, implying that immune processes within the gut may be a common feature and thus pointing to a potential nexus between the two diseases. The "Hematopoietic cell lineage" pathway emerged as one of the most statistically significant shared pathways. This observation aligns with clinical evidence where hematopoietic stem cell transplantation has proven effective in ameliorating symptoms of both Parkinson's and Crohn's disease,[57-58] highlighting the critical role of hematopoietic differentiation in their common mechanisms. Furthermore, the presence of the "TNF signaling pathway" is particularly salient, given that anti-TNF therapies for Crohn's disease are associated with a substantially reduced risk of developing Parkinson's disease.[59] The enrichment of the "Adipocytokine signaling pathway" lends further support to the role of aberrant lipid metabolism as a convergent process in both disorders, while the most statistically significant shared pathway, "HIF-1 signaling pathway", implicates hypoxia—a condition known to be pivotal in both Parkinson's[60] and Crohn's disease[61-63]—as a critical nexus linking mitochondrial dysfunction, oxidative stress, and impaired protein degradation.[64]

An exploration of the disease-specific pathways also yielded profound insights into both distinct and convergent mechanisms. For Parkinson's disease, the unique enrichment of "Ferroptosis" aligns with its known role in dopaminergic neuron death and glial activation,[65] while "Thermogenesis" provides a molecular correlate for the clinical observation of temperature sensitivity in patients with Parkinson's disease.[66-68] Intriguingly, longevity-regulating pathways were enriched in both diseases—"Longevity regulating pathway" and "mTOR signaling pathway" for Parkinson's disease, and "FoxO signaling pathway" for Crohn's disease—suggesting a deeper, shared connection to cellular aging processes that warrants further investigation. The Parkinson's specific enrichment of "Circadian rhythm"

supports the widespread prevalence of sleep and circadian disruptions in these patients.[69-70] Crucially, several pathways converged on the theme of cell adhesion. The Parkinson's specific "Rap1 signaling pathway", which governs cell-cell junction formation via integrin regulation, alongside the Crohn's specific "Cell adhesion molecules" and "Adherens junction" pathways, collectively point to compromised barrier function as a fundamental, albeit genetically distinct, feature. This is further reinforced by the Parkinson's specific "VEGF signaling pathway", a known mediator of blood-brain barrier damage.[53] Together, these results illustrate a complex etiological landscape where both shared and disease-specific pathways ultimately converge upon common pathological themes, suggesting a multifaceted basis for the comorbidity.

To elucidate if these genetically-implicated pathways were functionally active *in vivo*, we assessed their transcriptional activities across five disease-relevant tissues ("*Transcriptomic GO and pathway enrichment of Parkinson's and Crohn's disease*" in Experimental Section). A striking pattern emerged where Parkinson's and Crohn's genetic pathways were significantly engaged in the pathological processes of all five tissues (Figure 4b). Parkinson's specific pathways were pervasively downregulated in both substantia nigra and blood, indicative of a systemic degenerative state in Parkinson's disease. Notably, "Dopaminergic synapse" and "Serotonergic synapse" were suppressed not only in the Parkinson's substantia nigra but also in the Crohn's ileal and colonic mucosa. Given the direct communication between the brain and gut via the vagus nerve,[71] this concurrent downregulation suggests a potential trans-synaptic or neuro-inflammatory link between these distant tissues. Parkinson's specific "VEGF signaling pathway" was significantly upregulated in the Crohn's ileal and colonic mucosa. As a non-pathogenic pathway in these contexts, its activation may represent a compensatory response to repair the compromised mucosal barrier.[72-73] Crohn's specific pathways were generally upregulated in the Crohn's intestinal mucosa but displayed divergent activity patterns in Crohn's blood, suggesting distinct functional roles in systemic versus local compartments. Interestingly, Crohn's specific "Cell adhesion molecules" and "Adherens junction" pathways were significantly activated in the Parkinson's substantia nigra and blood. Since their activation can be a reparative response,[74] this signature hints at a pre-existing or ongoing compromise of the blood-brain barrier in Parkinson's disease. Finally, the shared genetic pathways were consistently activated across all five tissues, strongly suggesting a synergistic interplay that underpins the comorbidity.

To move beyond isolated analyses and investigate the coordinated behavior of the genetic association genes (313 genes for Parkinson's disease, 319 for Crohn's disease, and 31 for common), we calculated the transcriptional correlation of four gene sets, i.e., shared genes, Parkinson's specific genes, Crohn's specific genes, and all combined genes, within and across tissues using the SMIC algorithm ("*Transcriptomic gene and pathway correlation calculation of Parkinson's and Crohn's disease using signed maximal information coefficient*" in Experimental Section). Within the blood, a shared tissue, all four gene sets displayed positive correlation, with the shared gene set reaching statistical significance (SMIC = 0.33, $P < 0.05$), indicating a functional mechanistic link within the circulatory system (Figure S4, Supporting Information). As expected, correlations between the Crohn's ileal and colonic mucosa were exceptionally high across all gene sets (SMIC > 0.3, $P < 0.001$), confirming their profound molecular similarity. A striking and unexpected finding emerged from the cross-disease analysis: a consistent, positive correlation was observed between the Crohn's blood and the Parkinson's substantia nigra for all four gene sets, reaching statistical significance for the Crohn's specific and combined gene sets ($P < 0.05$ and $P < 0.01$). In contrast, the correlation between Parkinson's blood and substantia nigra was inconsistent. This critical asymmetry suggests that the pathological state of the blood in Crohn's disease, more so than in Parkinson's disease itself, is transcriptionally aligned with the pathological processes occurring in the Parkinsonian brain.

We then extended this correlational analysis to the pathway level, applying SMIC to the transcriptional activities of four corresponding sets of genetic pathways. While this again confirmed the strong positive correlation between the Crohn's ileal and colonic mucosa, other intra- and inter-tissue comparisons failed to yield consistent or significant results (Figure S5, Supporting Information), suggesting that simple correlation may be insufficient to capture the complexity of disease linkage. We therefore deployed the ACS method to quantify synergy, a more nuanced measure of synergistic activity ("*Transcriptomic pathway synergy measure of Parkinson's and Crohn's disease based on acting-in-concert score*" in Experimental Section). The ACS results revealed widespread synergistic relationships among the five disease tissues (Figure S6, Supporting Information), implying a high degree of functional influence.

Recognizing that pathway-level activity scores (e.g., NES) can obscure the individual contributions of member genes, we performed a more granular analysis by calculating both SMIC-based correlation and ACS-based synergy for each genetic pathway based on the

differential expression of its constituent genes. The correlation analysis again highlighted the strong, consistent relationship between the Crohn's ileum and colon but yielded few other significant findings (Figure S7a, Supporting Information). However, the synergy analysis produced several compelling insights (Figure S7b, Supporting Information). Beyond the robust synergy between the Crohn's ileal and colonic mucosa, we observed significant synergy for shared genetic pathways between Parkinson's and Crohn's blood, indicating a direct cooperative interaction within the circulation. More critically, a high degree of synergy for shared pathways was detected between Parkinson's substantia nigra and Crohn's blood, reinforcing the hypothesis that Crohn's systemic factors directly and synergistically impact central nervous system pathology in Parkinson's disease. Finally, we observed heightened synergistic scores for Crohn's specific pathways between Parkinson's substantia nigra and Crohn's colonic mucosa, providing further evidence for a direct gut-brain axis of interaction that contributes to the shared disease landscape.

2.5. Increased gut epithelial permeability facilitates ileal and colonic mucosal pathologies in Crohn's disease

Building upon the above discovery of intricate multi-tissue functional associations between Parkinson's and Crohn's disease, we next sought to establish a plausible physical basis for this pathological crosstalk. Given that Parkinson's and Crohn's disease are canonically defined by pathology primarily localized to the brain and intestine, respectively,[75-76] any molecular dialogue between them must navigate the gut-brain axis. This axis is anatomically fortified by a series of three sequential biological barriers: the gut epithelial barrier (GEB), the gut-vascular barrier (GVB), and the blood-brain barrier (BBB). We therefore posited a "sequential-breach" hypothesis, wherein molecular pathology originating in the Crohn's gut must progressively traverse these three checkpoints to exert a tangible influence on neuropathogenesis in the Parkinson's brain. The compromise of these barriers would thus represent the fundamental physical conduit for the observed comorbidity. Accordingly, our investigation first focused on interrogating the integrity of the initial line of defense—the GEB—within the context of active Crohn's pathology.

To empirically test this, we interrogated the transcriptomic profiles of the ileal and colonic mucosa from Crohn's patients, focusing on our curated panel of GEB permeability biomarkers. Our analysis revealed that a striking majority of these markers exhibited expression changes that were not only statistically significant but also directionally consistent

with the states indicative of impaired barrier function (**Figure 5**a; Table S16, Supporting Information). This provides compelling molecular evidence for the structural disruption of intercellular tight and adherens junctions in the Crohn's gut, leading to heightened epithelial permeability. This breach effectively dismantles the first physical safeguard, permitting the translocation of luminal contents into the lamina propria (Figure 5b). While the expression of most markers aligned with this conclusion, three biomarkers—claudin 1, claudin 2, and JAM3—displayed a consistent and significant transcriptional upregulation, a finding seemingly at odds with their protein-level functions in maintaining barrier integrity. As these are not Crohn's disease susceptibility genes, we propose this transcriptional induction may represent a compensatory, albeit insufficient, response to protein-level degradation or mislocalization, a complex regulatory feedback loop that warrants further mechanistic elucidation.

The consequence of this compromised GEB is an influx of microbial products and other luminal antigens into the intestinal wall, a perturbation expected to profoundly remodel the local biological network. To visualize these downstream effects, we integrated our transcriptomic activity data (pathway NES and *P*-values) with the foundational biological pathway network ("*Human biological pathway network construction*" in Experimental Section). By filtering for significantly perturbed pathways while preserving network connectivity, we constructed context-specific pathway networks for both the Crohn's ileum and colon (Figure 5c, d). The resultant networks were remarkably congruent, corroborating our prior correlational analyses and underscoring the profound mechanistic similarity between the two intestinal sites. Intriguingly, these networks retained several pathways without direct genetic links to Crohn's disease, including some with Parkinson's specific genetic underpinnings. Their topological persistence reveals their critical role as indispensable functional bridges that connect otherwise disconnected hubs of significantly altered Crohn's pathways. The specific inclusion of Parkinson's genetic pathways as such conduits within the Crohn's intestinal milieu provides compelling evidence for a latent molecular comorbidity at the gut level. While direct investigation of Parkinson's disease-related pathology in the ileum and colon remains a nascent field, our findings lay a novel conceptual groundwork and provide a strong impetus for future research into this unexplored facet of the gut-brain axis.

2.6. Gut-vascular barrier dysfunction underlies the blood-borne intersection of Parkinson's and Crohn's disease

We next assessed the integrity of the GVB, the second critical checkpoint in the gut-brain axis. To this end, we analyzed blood transcriptomes from both Parkinson's and Crohn's cohorts for permeability biomarker signatures. This analysis revealed a compelling transcriptomic profile of GVB impairment in Crohn's disease, with most biomarkers showing statistically robust expression changes indicative of increased permeability; conversely, these changes were largely non-significant in Parkinson's disease, suggesting the GVB remains substantially intact in this condition (**Figure 6**a; Table S17, Supporting Information). The paradoxical upregulation of claudin 5 in Crohn's blood, a potential compensatory response, was a notable exception. These transcriptomic signatures strongly suggest a compromised GVB in Crohn's disease, characterized by the disruption of its intercellular junctions, which facilitates the infiltration of gut-derived molecules into the bloodstream (Figure 6b).

To model the systemic consequences of this GVB breach in Crohn's disease, we constructed the blood-specific biological landscape for both Parkinson's and Crohn's disease (Figure 6c) by integrating transcriptomic activity onto the foundational pathway network ("*Human biological pathway network construction*" in Experimental Section). We then classified interaction for any same pathway in Parkinson's and Crohn's disease as either synergistic (both up- or down-regulated) or antagonistic (divergently regulated). The synergistic mode would theoretically promote comorbidity, while the antagonistic mode would counteract it. The landscape was overwhelmingly dominated by synergistic effects, revealing a powerful systemic synergy. Antagonistic interactions were rare and confined to the network's periphery, exerting negligible global influence. This systemic synergy provides a molecular basis for how the pathological milieu in Crohn's blood could create a permissive environment for Parkinson's pathogenesis. Notably, the network's structural integrity relied on several non-genetically associated "bridge" pathways, highlighting their critical role in mediating this pathological crosstalk and marking them as targets for future investigation.

2.7. Crohn's blood signature promotes substantia nigra degeneration in Parkinson's disease through blood-brain barrier disruption

Our investigation culminated at the final and most critical gatekeeper of the gut-brain axis, BBB. We sought to determine if this terminal interface is breached under the pathological conditions of Crohn's or Parkinson's disease, thereby permitting the influx of peripheral molecules into the brain parenchyma.

A transcriptomic interrogation of permeability biomarkers yielded unambiguous evidence (**Figure 7**a; Table S18, Supporting Information). In the blood of patients with Crohn's disease, the entire panel of BBB markers exhibited expression changes that were both statistically robust and directionally consistent with compromised barrier integrity. In contrast, these markers remained largely quiescent in Parkinson's blood, suggesting that the systemic milieu in Parkinson's disease does not induce a BBB breach. However, a direct analysis of the Parkinson's substantia nigra painted a different picture, revealing a significant local disruption of the BBB. This dual-front assault on the BBB—a systemic challenge from the Crohn's periphery and a localized compromise from intrinsic Parkinson's pathology—creates a permissive gateway for pathological crosstalk (Figure 7b). Notably, the paradoxical transcriptional upregulation of claudin 5 and JAM3 within the Parkinson's substantia nigra suggests a putative, albeit insufficient, compensatory response to protein-level junctional instability.

To delineate the functional architecture of the diseased brain following this BBB breach, we constructed a substantia nigra-specific pathological network (Figure 7c) by integrating transcriptomic activity data onto the foundational pathway landscape ("*Human biological pathway network construction*" in Experimental Section). The resulting network was dominated by pervasive pathway downregulations, a molecular portrait of the degenerative state characteristic of the Parkinson's brain. Critically, the network's structural integrity was maintained by several topological keystones, including pathways with specific genetic links to Crohn's disease. These pathways, though not directly implicated in Parkinson's genetics, serve as indispensable functional conduits connecting significantly altered Parkinson's disease-centric hubs. The presence of these Crohn's specific pathways within the brain pathological network in Parkinson's disease provides a tantalizing glimpse into a latent molecular comorbidity within the brain itself. This finding posits a novel mechanism for the comorbidity, suggesting that systemic factors in Crohn's disease may directly engage and exacerbate the intrinsic pathological cascades of Parkinson's disease, a hypothesis that opens a new frontier for research into the gut-brain connection in neurodegeneration.

3. Discussion

In this study, the multi-scale systems biology investigation, spanning from genetic variants to tissue-specific transcriptional networks, converges on a cohesive and compelling mechanistic framework for the comorbidity between Parkinson's and Crohn's disease. A "gut-blood-brain

axis" model is proposed to elucidate a plausible, directional cascade through which peripheral intestinal pathology in Crohn's disease may directly promote neurodegeneration in Parkinson's disease (**Figure 8**). This model posits a sequential breach of three critical biological barriers. The process is initiated by a compromised gut epithelial barrier in the Crohn's ileum and colon (Figure 8a), which permits the translocation of luminal antigens and microbial products, thereby remodeling the local mucosal pathobiology (Figure 8b, c). This is followed by the permeabilization of the gut-vascular barrier, leading to the systemic dissemination of these pro-inflammatory molecules into the bloodstream (Figure 8d). Our analysis reveals that this creates a systemic milieu in Crohn's blood that not only acts synergistically with that in Parkinson's blood (Figure 8e) but also is transcriptionally aligned with the pathological state of the Parkinson's substantia nigra. The cascade culminates in the compromise of the blood-brain barrier, a dual-front assault driven by both systemic factors from the Crohn's periphery and intrinsic pathology within the Parkinson's substantia nigra (Figure 8f), ultimately allowing peripheral insults to engage and exacerbate central nervous system degeneration (Figure 8g). This model provides, for the first time, a tangible physical and molecular basis for the well-documented epidemiological link between these two seemingly disparate disorders.

A key strength of our study lies in its integrative, systems-level design, which bridges the gap between static genetic risk and dynamic, tissue-specific functional consequences. By employing novel computational approaches such as SMIC and our newly proposed ACS, we were able to move beyond simple correlation to uncover complex, non-linear relationships and synergistic interplay between pathways and tissues. This methodology provides a powerful blueprint for investigating other complex comorbidities, particularly those spanning the gut-brain axis. Our findings redefine the etiological landscape of Parkinson's disease by positioning peripheral inflammatory conditions not merely as risk factors, but as active participants in neuropathogenesis, offering a paradigm shift that could inform new diagnostic and therapeutic strategies focused on maintaining gut barrier integrity and mitigating systemic inflammation to preserve neurological health.

While our data-driven discoveries provide a robust framework, we acknowledge several limitations that chart a clear course for future research. Foremost, our findings are computationally derived and constitute a rich portfolio of data-driven hypotheses that await rigorous experimental validation. Methodologically, our ACS metric represents a prototype

approach; future iterations could incorporate the magnitude of gene expression changes, not just the direction, to achieve a more quantitative measure of synergy. Furthermore, validation across multi-omic layers—including proteomics and metabolomics—is imperative to capture post-transcriptional nuances and confirm that the observed transcriptional synergies translate to the functional protein and metabolite levels. The current analysis is also constrained by the availability of matched tissue datasets. Acquiring transcriptomic data from the substantia nigra in Crohn's disease and the Parkinson's intestinal mucosa represents a critical next step to complete the mechanistic puzzle. Finally, leveraging the power of single-cell and spatial transcriptomics will be crucial for dissecting the cell-type-specific contributions to barrier dysfunction, and intra- and inter-tissue crosstalk, elevating the resolution of our proposed comorbidity model from the tissue to the cellular level.

4. Experimental Section

Genetic association data curation: We utilized a tailored pipeline (Figure 1a) to retrieve, aggregate and normalize genetic association data for Parkinson's and Crohn's disease. Specifically, in the light of the unbiased nature of GWAS to unearth genetic variants across whole genome,[77] PheGenI[78] was leveraged to obtain GWAS data of Parkinson's and Crohn's disease. Only variants which surpass genome-wide significant threshold were kept. Considering complex disorder phenotypes, such as Parkinson's and Crohn's disease, are typically featured by synergistic variants with very small or mild individual effects,[79] genetic factors not satisfying stringent cutoff but with suggestive or nominal associations might virtually matter. So, candidate gene-based genetic association studies as complements were also taken into consideration. This kind of studies has two- (or three-) fold evidence: pre-study biological hints, within-study conclusions (and post-study validations). The original publications were gained from PubMed.

Due to the fact that MeSH term labelling is time-consuming and lagging,[80-81] PubMed search using MeSH terms would undoubtedly omit quite a lot of related literature. Thus, in order to fetch most relevant publications indexed in PubMed, we revised our previous literature retrieval terms[82] as "Parkinson* AND (Polymorphism OR Genotype OR Alleles) NOT Neoplasms" and "Crohn* AND (Polymorphism OR Genotype OR Alleles) NOT Neoplasms" for Parkinson's and Crohn's disease, respectively. Non-English-written papers were removed. All abstracts were scanned and only genetic association studies reporting significant genetic associations with Parkinson's and Crohn's disease from retrieved publication corpus were

included for in-detailed selection. Further, full contents of all qualified papers were reviewed to ensure the consistency of those drawn conclusions.

To converge irregular variants into a uniform corpus, several tools were adopted for final variant standardization. UCSC liftOver[83] was utilized to calibrate Parkinson's and Crohn's disease related variants from various genome coordinate versions to GRCh38 assembly. SNPedia,[84] LitVar,[85] and ClinVar[86] were used to normalize polymorphic sites into standard formats.

Monte Carlo experiment was implemented to testify if variant- and gene-level commonalities between Parkinson's and Crohn's disease are biologically meaningful or statistically random. Specifically, let *G* designate whole number of human variants (667,501,404 live Ref SNPs in NCBI dbSNP Database) / genes (61,197 in NCBI Entrez Gene Database). Let *P* and *C* denote the variant/gene sizes related to Parkinson's and Crohn's disease separately. We randomly chose variants with the same number as Parkinson's and Crohn's ones from the aforementioned live Ref SNPs and genes 100,000 times distinctively, and the empirical *P*-value was calculated as the number of sets of overlapping variants/genes no less than the real observed common size N divided by 100,000. The final *P*-value could be given by the following formula:

$$P_1(X \geq N|G,P,C) = \frac{1}{T}\sum_{i=1}^{T} S_i \quad (1)$$

$$S_i = \begin{cases} 0, & \text{if } |P_i \cap C_i| < N \\ 1, & \text{if } |P_i \cap C_i| \geq N \end{cases} \quad (2)$$

where T is constant 100,000, S_i is a Boolean variable indicating the status in the i-th experiment, P_i and C_i are variant / gene sets of Parkinson's and Crohn's disease correspondingly.

Bio-functional aggregation of genetic association data: Capitalizing on latest GO and pathway knowledgebase—KEGG, clusterProfiler[87] was leveraged to detect biological meanings hidden behind Parkinson's and Crohn's genetic association genes. GO provides the world's largest information multiplicity source on gene function, saturated with BP, CC, and MF facets. Described as a directed acyclic graph, GO possesses loose hierarchies in which child (leaf) items are more specialized and concrete than corresponding parent (root) terms. With the notion that leaf GO terms are more informative than root terms, a customized strategy was used in the current study: leaf enriched GO terms were picked as potent agents

for biology-level interpretations. All overrepresented GO / pathway terms were further refined by multiple testing correction with false positive rate (FDR) value 0.05 as significance threshold.

Human biological pathway network construction: Distinctive biological pathways act in a concerted manner to organize micro- and macro-phenotypes. However, current biological pathways are largely discrete and need to be weaved together. Our previous work attempted solving this problem using network separation distance metric.[88] In present study, this framework was implemented in the context of a high-quality human protein interactome[89]. Albeit lots of pathway resources have been available, such as KEGG[44], reactome,[90] pathway definitions and criteria of these databases differ from each other, and merging or comparing various pathway resources is a pretty arduous task. As a widely used pathway source, only KEGG pathway system was used to construct human biological pathway network. KEGG pathways belonging to the category "Human Diseases" were filtered out for further analysis, because pathways of this category are meta-pathways, i.e., merged version of many involved pathways, not reflecting the original physiological profiles inside human cells. Members of a pathway tend to converge into one or more module(s) in the context of human interactome. Pathways with significant network modularity were deemed real biological pathways and retained. As indicated by our previous work,[88] network distance between two pathways should be negative if this pathway pair has connections, thus pathways with network separation distance less than zero were kept.

Transcriptomic meta-analysis of Parkinson's and Crohn's disease: Transcriptome is able to figure out how the genetic factors virtually function. Parkinson's and Crohn's transcriptomic data were fetched from GEO, SRA, and ArrayExpress. As the most affected sites, substantia nigra transcriptome data were used for Parkinson's disease, and colonic and ileal mucosa ones for Crohn's disease. Owing to currently no transcriptomic dataset(s) of individual patients with both Parkinson's and Crohn's disease and the fact that blood transcriptomic profiling has proved to be unbiased and shown efficacy in idiopathic Parkinson's and Crohn's patients diagnosis,[91-94] as a compromise, peripheral blood datasets in either Parkinson's or Crohn's disease were used for preliminary dissection of etiological linkages between these two disorders. The detailed information of transcriptomic data collection and processing used in this study can be found in our recent work,[43] where a new transcriptomic *meta-analysis* method, AWmeta, was proposed to aggregate multiple Parkinson's or Crohn's transcriptomic

data in these five tissues for robust differentially expressed genes (DEGs) with reliable fold change (FC) and corrected *P*-value, respectively.

Transcriptomic GO and pathway enrichment of Parkinson's and Crohn's disease: To elucidate the functional manifestation of the genetic architecture in relevant tissues, we performed a multi-level transcriptomic analysis. First, we identified DEGs from our transcriptomic meta-analyses across five disease-relevant contexts: the substantia nigra and blood in Parkinson's disease, and the ileal and colonic mucosa and blood in Crohn's disease (see "*Transcriptomic meta-analysis of Parkinson's and Crohn's disease*" section for details). A stringent statistical threshold of $|\log_2 FC| > \log_2 1.5$ and $P < 0.05$ was applied to define the DEG sets. Subsequently, to comprehensively map the functional landscape, we conducted enrichment analyses for both GO terms and biological pathways using two complementary algorithms: Over-Representation Analysis (ORA) on the DEG sets and Gene Set Enrichment Analysis (GSEA) on the complete ranked gene lists.[95] To leverage the unique strengths of both methods, we adopted a consolidated approach, assigning the minimum *P*-value obtained from either ORA or GSEA as the definitive significance score for each item.

Finally, to quantify the functional activity of key biological processes identified at the genetic level, we focused on the previously identified GO hotspots and the genetically-implicated biological pathways. We utilized NES derived from GSEA as a robust metric to represent the activation or suppression status of these specific pathways and GO terms within each of the five disease-tissue profiles.

Transcriptomic genes and pathway correlation calculation of Parkinson's and Crohn's disease using signed maximal information coefficient: To interrogate the associative relationships between transcriptional signatures in Parkinson's and Crohn's disease at both the gene and pathway levels, we sought a metric capable of transcending the limitations of conventional linear correlation measures. Recognizing that biological systems are governed by complex and often non-linear dynamics, we employed a robust approach based on the maximal information coefficient (MIC), a novel measure of dependence that excels at detecting a wide spectrum of both linear and non-linear associations with high statistical power.[96] However, as an unsigned metric, MIC quantifies the strength but not the directionality of an association. To preserve this critical information, we implemented a signed version, the signed maximal information coefficient (SMIC), by integrating the MIC

value with the directionality provided by the Spearman's rank correlation coefficient (ρ). The SMIC between two variables, X and Y, is formally defined as:

$$\mathrm{SMIC}_{\mathrm{X,Y}} = \mathrm{sign}_{\rho}(\mathrm{X,Y}) \times \mathrm{MIC} \quad (3)$$

where $\mathrm{sign}_{\rho}(\mathrm{X,Y})$ denotes the sign (+1 or −1) of the Spearman correlation. MIC values were computed using the minerva R package.[97] This hybrid approach allows us to capture the full complexity of transcriptional relationships while retaining an intuitive understanding of the crucial directional context.

Transcriptomic pathway synergy measure of Parkinson's and Crohn's disease based on acting-in-concert score: Recognizing that simple correlation metrics are often insufficient to capture the intricate interplay between complex diseases, we moved beyond simple pairwise associations to quantify functional cooperativity at the pathway level. The overall activity of a shared biological pathway can be misleading, as it may obscure critical synergistic or antagonistic behaviors among its constituent members. To dissect these sub-pathway dynamics, we conceptualized and implemented a novel metric, the acting-in-concert score (ACS), designed to quantify the degree of concordant regulation within a given pathway across two disease states.

We define a gene as "acting in concert" if it is directionally consistent in its dysregulation, i.e., up- or down-regulated in both diseases. The ACS for a given pathway is then formally calculated as:

$$\mathrm{ACS} = \frac{\mathrm{N_{AC}}}{\mathrm{N}} - 0.5 \quad (4)$$

where $\mathrm{N_{AC}}$ is the number of constituent genes acting in concert, and N is the total number of genes in the pathway. A positive ACS signifies a net synergistic propensity within the pathway, suggesting that the pathological states of the two diseases reinforce each other, while a negative ACS indicates a predominantly antagonistic relationship.

Intestinal and brain barrier permeability biomarker collection: To evaluate the integrity of key biological interfaces implicated in the gut-brain axis, we curated comprehensive panels of molecular biomarkers based on an extensive literature review. Recognizing that compromised barrier function is a pivotal event in initiating and perpetuating pathological inflammatory and neurodegenerative cascades, we focused on three critical barriers. First, for GEB, which delineates the intestinal lumen from the lamina propria and serves as the primary sentinel

against the translocation of luminal pathogens and antigens,[98] we compiled a list of established permeability markers (Table S16, Supporting Information). Subsequently, we collated a set of indicators reflective of the integrity of GVB, a crucial checkpoint that restricts the passage of microbial derivatives from the intestinal interstitium into systemic circulation, thereby preventing systemic dissemination and end-organ damage (Table S17, Supporting Information).[99] Finally, to probe the status of the central nervous system interface, we assembled a panel of well-characterized biomarkers for BBB, a highly selective physiological boundary that meticulously regulates molecular traffic between the periphery and the brain parenchyma to safeguard neural homeostasis against blood-borne insults (Table S18, Supporting Information).[100]

Acknowledgements

The authors are grateful to the anonymous experts for insightful reviews and members of Ming Chen's laboratory for helpful discussions and valuable comments. This work was supported by the National Key Research and Development Program of China (2023YFE0112300), National Natural Sciences Foundation of China (32261133526; 32270709; 32070677), the 151 talent project of Zhejiang Province (first level), the Science and Technology Innovation Leading Scientist (2022R52035).

Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article.

Figure Legends

Figure 1. Variant-centric dissection reveals a shared genetic architecture of Parkinson's and Crohn's disease. **a**, Retrieval, integration, and standardization process of Parkinson's and Crohn's genetic variants. **b**, Statistics of initial PubMed retrieval, filtration, and final genetic variants and genes relevant to Parkinson's and Crohn's disease. **c**–**e**, Literature-derived variant-to-gene mapping showcases significant variant and gene intersections between Parkinson's and Crohn's disease. The gene intersection can be derived from common variants (Parkinson's & Crohn's common-to-common mapping) or disease-specific variants (Parkinson's or Crohn's specific-to-common mapping) (**c**), and these variant (**d**) and gene (**e**) intersections are statistically significant, with empirical *P*-value

determined by 100,000 Monte Carlo experiments. **f**, Functional consequences of Parkinson's and Crohn's genetic variants. **g**, Functional consequences of Parkinson's and Crohn's genetic genes. **h**, Functional consequences of Parkinson's and Crohn's predicted genes. PD, Parkinson's disease; CD, Crohn's disease.

Figure 2. Genetic variants of Parkinson's and Crohn's disease converge on pathogen- and derivative-induced infection, recognition and resistance and barrier integrity. **a**, Broad GO terms enriched by genetic association genes in Parkinson's and Crohn's disease. The x-axis represents the number of genes included in the enriched GO terms (y-axis). Red, purple, and green indicate GO-BP, GO-MF, and GO-CC, respectively. **b**, The same significantly enriched GO-BP terms (top 40) for genetic association genes in both Parkinson's and Crohn's disease. **c**, Significantly enriched GO-MF and GO-CC terms for genetic association genes in Parkinson's and Crohn's disease. The x-axis represents the enrichment ratio of the enriched GO terms (y-axis). The sphere size indicates the number of genes enriched in each GO term, and the sphere color the enrichment significance. GO term name in red denotes the same GO terms enriched by genetic association genes in both Parkinson's and Crohn's disease within the GO-MF and GO-CC categories. GO terms marked with red asterisks are GO hotspots, whose transcriptional activities in multiple disease tissues were quantified in Figure 3.

Figure 3. Tissue-wise transcriptional activities of GO hotspots in Parkinson's and Crohn's disease. Pink shading indicates GO hotspots related to the recognition and resistance of pathogens and their relevant derivatives, and green shading those related to neural activity. NES is used to quantify transcriptional activities of GO hotspots in Parkinson's and Crohn's tissues, with red shading representing activation and blue shading repression. FDR with green shading indicates corresponding activity quantification is statistically significant.

Figure 4. Genetic variant-enriched pathways are functionally active across tissues in Parkinson's and Crohn's disease. **a**, Enriched non-disease pathways for genetic variants in Parkinson's and Crohn's disease. This pathway enrichment was done against biological pathways within KEGG non-disease categories by ORA approach, with FDR, enrichment ratio and gene counts shown in Parkinson's and Crohn's specific and common pathway classes. **b**, Tissue-wise transcriptional activities of genetic variant-enriched pathways in Parkinson's and Crohn's disease. NES is used to quantify transcriptional activities of genetic pathways in Parkinson's and Crohn's tissues, with red shading representing activation and blue shading repression. FDR with green shading indicates corresponding activity quantification is statistically significant.

Figure 5. Increased intestinal epithelial permeability facilitates ileal and colonic mucosal pathologies in Crohn's disease. **a**, Transcriptional change profile of gut epithelial barrier permeability biomarkers

in ileal and colonic mucosa of Crohn's disease. **b**, Schematic diagram of the mechanism underlying increased gut epithelial barrier permeability in the ileum and colon of Crohn's disease. **c**, Biological pathway network in ileal mucosa of Crohn's disease. **d**, Biological pathway network in colonic mucosa of Crohn's disease. The thickness of the edges between pathway nodes represents the pathway crosstalk intensity: the thicker the edge, the greater the crosstalk intensity. The pathway node size denotes the network node degree: the larger the node, the higher the node degree. IM, ileal mucosa. CM, colonic mucosa. FC, fold change. NES, normalized enrichment score. FDR, false discovery rate. GEB, gut epithelial barrier. TJ, tight junction. AJ, adherens junction.

Figure 6. Gut-vascular barrier dysfunction underlies the blood-borne intersection of Parkinson's and Crohn's disease. **a**, Transcriptional change profile of gut-vascular barrier permeability biomarkers in blood of Parkinson's and Crohn's disease. **b**, Schematic diagram of the mechanism underlying increased gut-vascular barrier permeability in Parkinson's and Crohn's disease. **c**, Biological pathway network in blood of Parkinson's and Crohn's disease. The thickness of the edges between pathway nodes represents the pathway crosstalk intensity: the thicker the edge, the greater the crosstalk intensity. The pathway node size denotes the network node degree: the larger the node, the higher the node degree. WB, whole blood. FC, fold change. NES, normalized enrichment score. FDR, false discovery rate. GVB, gut-vascular barrier. TJ, tight junction. AJ, adherens junction.

Figure 7. Crohn's blood signature promotes substantia nigra degeneration in Parkinson's disease through blood-brain barrier disruption**.** **a**, Transcriptional change profile of blood-brain barrier permeability biomarkers in blood of Parkinson's and Crohn's disease, and substantia nigra of Parkinson's disease. **b**, Schematic diagram of the mechanism underlying increased blood-brain barrier permeability in Parkinson's and Crohn's disease. **c**, Biological pathway network in substantia nigra of Parkinson's disease. The thickness of the edges between pathway nodes represents the pathway crosstalk intensity: the thicker the edge, the greater the crosstalk intensity. The pathway node size denotes the network node degree: the larger the node, the higher the node degree. WB, whole blood. SN, substantia nigra. FC, fold change. FDR, false discovery rate. BBB, blood-brain barrier. TJ, tight junction.

Figure 8. Gut-blood-brain axis model for the comorbidity between Parkinson's and Crohn's disease**.** In the molecular pathological process of Crohn's disease, the gut epithelial barriers of the ileal and colonic mucosa are impaired (**a**), allowing the contents of the intestinal lumen to cross the barrier and enter the inner wall of the intestine. This further affects the biological pathway networks in the ileal (**b**) and colonic (**c**) mucosa of Crohn's disease. Subsequently, the gut-vascular barrier is damaged (**d**), causing microorganisms and their derivatives to cross the barrier and enter the blood circulation, which in turn impacts the blood biological pathway networks of Parkinson's and Crohn's disease (**e**).

Finally, against the background of Crohn's disease related blood pathology, the blood-brain barrier is impaired (**f**), enabling blood contents to cross the blockade and enter the brain parenchyma, thereby influencing the biological pathway network in the substantia nigra of the Parkinson's brain (**g**). GEB, gut epithelial barrier. GVB, gut-vascular barrier. BBB, blood-brain barrier. TJ, tight junction. AJ, adherens junction.

References

[1] V. L. Feigin, A. A. Abajobir, K. H. Abate, et al., *Lancet Neurol.* **2017**, *16* (11), 877.

[2] E. R. Dorsey, A. Elbaz, E. Nichols, et al., *Lancet Neurol.* **2018**, *17* (11), 939.

[3] E. Dorsey, T. Sherer, M. S. Okun, B. R. Bloem, *J. Parkinsons Dis.* **2018**, *8* (s1), S3.

[4] G. A. Roth, D. Abate, K. H. Abate, et al., *The Lancet* **2018**, *392* (10159), 1736.

[5] M. A. Nalls, C. Blauwendraat, C. L. Vallerga, et al., *Lancet Neurol.* **2019**, *18* (12), 1091.

[6] D. Chang, M. A. Nalls, I. B. Hallgrímsdóttir, et al., *Nat. Genet.* **2017**, *49* (10), 1511.

[7] W. Maetzler, D. Berg, *Nat. Rev. Neurol.* **2018**, *14* (2), 70.

[8] N. The Lancet, *Lancet Neurol.* **2018**, *17* (4), 289.

[9] D. C. Baumgart, W. J. Sandborn, *The Lancet* **2012**, *380* (9853), 1590.

[10] S. C. Ng, H. Y. Shi, N. Hamidi, et al., *The Lancet* **2017**, *390* (10114), 2769.

[11] R. Shivashankar, W. J. Tremaine, W. S. Harmsen, E. V. Loftus, *Clin. Gastroenterol. Hepatol.* **2017**, *15* (6), 857.

[12] J. Torres, S. Mehandru, J.-F. Colombel, L. Peyrin-Biroulet, *The Lancet* **2017**, *389* (10080), 1741.

[13] K. M. de Lange, L. Moutsianas, J. C. Lee, et al., *Nat. Genet.* **2017**, *49* (2), 256.

[14] M. C. Serra, A. Landry, J. L. Juncos, et al., *Neurourol. Urodyn.* **2018**, *37* (4), 1344.

[15] M. C. Houser, M. G. Tansey, *npj Parkinsons Dis.* **2017**, *3* (1), 3.

[16] R. A. Liddle, *Brain Res.* **2018**, *1693*, 201.

[17] P. Weimers, J. Halfvarson, M. C. Sachs, et al., *Gut* **2019**, *68* (1), 175.

[18] M. Rolli-Derkinderen, L. Leclair-Visonneau, A. Bourreille, et al., *J. Neurol.* **2019**, 1.

[19] S. Hutfless, G. K. Wenning, *Gut* **2019**, *68* (1), 3.

[20] M. A. Nalls, M. Saad, A. J. Noyce, et al., *Hum. Mol. Genet.* **2014**, *23* (3), 831.

[21] A. Witoelar, I. E. Jansen, Y. Wang, et al., *JAMA Neurol.* **2017**, *74* (7), 780.

[22] X. Kang, A. Ploner, Y. Wang, et al., *Brain Communications* **2023**, *5* (1), fcad002.

[23] M. E. Kars, Y. Wu, P. D. Stenson, et al., *Genome Med.* **2024**, *16* (1), 66.

[24] K. Y. Hui, H. Fernandez-Hernandez, J. Hu, et al., *Sci. Transl. Med.* **2018**, *10* (423), eaai7795.

[25] J.-C. Lin, C.-S. Lin, C.-W. Hsu, C.-L. Lin, C.-H. Kao, *Inflamm. Bowel Dis.* **2016**, *22* (5), 1049.

[26] P. Weimers, J. Halfvarson, M. C. Sachs, et al., *Inflamm. Bowel Dis.* **2019**, *25* (1), 111.

[27] M. Villumsen, S. Aznar, B. Pakkenberg, T. Jess, T. Brudek, *Gut* **2019**, *68* (1), 18.

[28] I. Peter, M. Dubinsky, S. Bressman, et al., *JAMA Neurol.* **2018**, *75* (8), 939.

[29] S. Park, J. Kim, J. Chun, et al., *J Clin Med.* **2019**, *8* (8), 1191.

[30] J. Pinel-Ríos, C. J. Madrid-Navarro, M. J. Pérez-Navarro, et al., *Parkinsonism Relat. Disord.* **2018**, *57*, 78.

[31] H.-S. Lee, E. Lobbestael, S. Vermeire, J. Sabino, I. Cleynen, *Gut* **2021**, *70* (2), gutjnl.

[32] R. D. Bell, E. A. Winkler, I. Singh, et al., *Nature* **2012**, *485* (7399), 512.

[33] B. Poller, J. Drewe, S. Krähenbühl, J. Huwyler, H. Gutmann, *Cellular and Molecular Neurobiology* **2009**, *30* (1), 63.

[34] X. Lu, M. Wang, J. Qi, et al., *Journal of Biological Chemistry* **2006**, *281* (9), 5895.

[35] J. Chen, C. Zhang, Y. Wu, D. Zhang, *Neuroepidemiology* **2019**, *52* (3-4), 181.

[36] Z. Mao, C. Liu, S. Ji, et al., *Neurochemical Research* **2017**, *42* (4), 1104.

[37] A.-C. Villani, M. Lemire, G. Fortin, et al., *Nature Genetics* **2008**, *41* (1), 71.

[38] E. F. Stavrou, F. Chatzopoulou, C. Antonatos, et al., *Pharmacogenetics and Genomics* **2022**, *32* (6), 235.

[39] M. Patel, S. Singh, *Neurotoxicity Research* **2022**, *40* (4), 941.

[40] K. Y. Hui, H. Fernandez-Hernandez, J. Hu, et al., *Science Translational Medicine* **2018**, *10* (423), eaai7795.

[41] P. Derkinderen, M. Neunlist, *Nature Reviews Gastroenterology & Hepatology* **2018**, *15* (6), 330.

[42] F. P. Grenn, M. B. Makarious, S. Bandres-Ciga, et al., *Brain Communications* **2022**, *4* (6), fcac277.

[43] Y. Hu, Z. Wang, Y. Hu, et al., *bioRxiv* **2025**, 2025.05. 06.650408.

[44] M. Kanehisa, Y. Sato, M. Furumichi, K. Morishima, M. Tanabe, *Nucleic Acids Res.* **2019**, *47* (D1), D590.

[45] A. Camacho-Soto, A. Gross, S. Searles Nielsen, N. Dey, B. A. Racette, *Parkinsonism & Related Disorders* **2018**, *50* (1), 23.

[46] H. S. Lee, E. Lobbestael, S. Vermeire, J. Sabino, I. Cleynen, *Gut* **2021**, *70* (2), 408.

[47] I. Alecu, S. A. L. Bennett, *Frontiers in Neuroscience* **2019**, *13* (1), 328.

[48] E. A. Scoville, M. M. Allaman, C. T. Brown, et al., *Metabolomics* **2017**, *14* (1), 17.
[49] A. Davies, A. Nixon, K. Tsintzas, F. B. Stephens, G. W. Moran, *Clinical Nutrition ESPEN* **2021**, *41* (1), 305.
[50] D. Athauda, T. Foltynie, *Progress in Neurobiology* **2016**, *145-146* (1), 98.
[51] M. Anzola, *Journal of Viral Hepatitis* **2004**, *11* (5), 383.
[52] Y. Liao, J. Wang, E. J. Jaehnig, Z. Shi, B. Zhang, *Nucleic Acids Research* **2019**, *47* (W1), W199.
[53] G. Lan, P. Wang, R. B. Chan, et al., *Glia* **2021**, *70* (2), 337.
[54] R. Bouziat, B. Jabri, *Science* **2015**, *350* (6262), 742.
[55] I. Spadoni, E. Zagato, A. Bertocchi, et al., *Science* **2015**, *350* (6262), 830.
[56] N. K. Archer, N. D. Adappa, J. N. Palmer, et al., *Infection and Immunity* **2016**, *84* (12), 3575.
[57] C. A. DiNicola, A. Zand, D. W. Hommes, *Expert Opinion on Biological Therapy* **2017**, *17* (5), 555.
[58] W. Altarche-Xifro, U. di Vicino, M. I. Muñoz-Martin, et al., *EBioMedicine* **2016**, *8* (1), 83.
[59] I. Peter, M. Dubinsky, S. Bressman, et al., *JAMA Neurology* **2018**, *75* (8), 939.
[60] F. Rey, L. Messa, E. Maghraby, et al., *Antioxidants & Redox Signaling* **2023**, *38* (1-3), 160.
[61] E. L. Kerber, C. Padberg, N. Koll, et al., *International Journal of Molecular Sciences* **2020**, *21* (22), 8551.
[62] R. G. Sawyer, M. D. Spengler, R. B. Adams, T. L. Pruett, *Annals of Surgery* **1991**, *213* (3), 253.
[63] M. C. Manresa, C. T. Taylor, *Cellular and Molecular Gastroenterology and Hepatology* **2017**, *3* (3), 303.
[64] L. Leston Pinilla, A. Ugun-Klusek, S. Rutella, L. A. De Girolamo, *Biology* **2021**, *10* (8), 723.
[65] Z.-L. Wang, L. Yuan, W. Li, J.-Y. Li, *Trends in Molecular Medicine* **2022**, *28* (4), 258.
[66] G. Zhong, S. Bolitho, R. Grunstein, S. L. Naismith, S. J. G. Lewis, *PLoS One* **2013**, *8* (8), e72661.
[67] W. H. Jost, *International Review of Neurobiology* **2017**, *134* (1), 771.
[68] E. A. Coon, P. A. Low, *Handbook of Clinical Neurology* **2018**, *157* (1), 715.
[69] W.-Y. Cheng, Y.-S. Ho, R. C.-C. Chang, *Ageing Research Reviews* **2022**, *78* (1), 101620.

[70] Y. Shen, Q.-k. Lv, W.-y. Xie, et al., *Translational Neurodegeneration* **2023**, *12* (1), 8.
[71] M. M. Kaelberer, K. L. Buchanan, M. E. Klein, et al., *Science* **2018**, *361* (6408), eaat5236.
[72] O. Martin-Rodriguez, T. Gauthier, F. Bonnefoy, et al., *Frontiers in Immunology* **2021**, *12* (1), 754475.
[73] V. M. Abramov, I. V. Kosarev, T. V. Priputnevich, et al., *International Journal of Biological Macromolecules* **2021**, *189* (1), 410.
[74] A. Aggarwal, I. Singh, R. Sandhir, *Neurochemistry International* **2018**, *118* (1), 205.
[75] W. Poewe, K. Seppi, C. M. Tanner, et al., *Nature Reviews Disease Primers* **2017**, *3* (1), 17013.
[76] G. Roda, S. Chien Ng, P. G. Kotze, et al., *Nature Reviews Disease Primers* **2020**, *6* (1), 22.
[77] K. J. Karczewski, M. P. Snyder, *Nat. Rev. Genet.* **2018**, *19* (5), 299.
[78] E. M. Ramos, D. Hoffman, H. A. Junkins, et al., *European Journal of Human Genetics* **2013**, *22* (1), 144.
[79] V. Tam, N. Patel, M. Turcotte, et al., *Nat. Rev. Genet.* **2019**, *20* (8), 467.
[80] S. Dai, R. You, Z. Lu, et al., *Bioinformatics* **2019**, *36* (5), 1533.
[81] G. Xun, K. Jha, Y. Yuan, et al., *Bioinformatics* **2019**, *35* (19), 3794.
[82] Y. Hu, Z. Pan, Y. Hu, L. Zhang, J. Wang, *Mol. Neurobiol.* **2017**, *54* (6), 4452.
[83] P. A. Fujita, B. Rhead, A. S. Zweig, et al., *Nucleic Acids Res.* **2011**, *39* (suppl_1), D876.
[84] M. Cariaso, G. Lennon, *Nucleic Acids Res.* **2012**, *40* (D1), D1308.
[85] A. Allot, Y. Peng, C.-H. Wei, et al., *Nucleic Acids Res.* **2018**, *46* (W1), W530.
[86] M. J. Landrum, J. M. Lee, M. Benson, et al., *Nucleic Acids Res.* **2018**, *46* (D1), D1062.
[87] G. Yu, L.-G. Wang, Y. Han, Q.-Y. He, *OMICS: J. Integrative Biol.* **2012**, *16* (5), 284.
[88] Y. Hu, Y. Yang, Z. Fang, et al., *Methods* **2017**, *131* (Supplement C), 93.
[89] Y.-S. Hu, J. Xin, Y. Hu, L. Zhang, J. Wang, *Alzheimers Res. Ther.* **2017**, *9* (1), 29.
[90] B. Jassal, L. Matthews, G. Viteri, et al., *Nucleic Acids Res.* **2019**, *48* (D1), D498.
[91] R. Shamir, C. Klein, D. Amar, et al., *Neurology* **2017**, *89* (16), 1676.
[92] P. Chen, G. Zhou, J. Lin, et al., *Frontiers in Medicine* **2020**, *7*, 123.
[93] Y. Iturria-Medina, A. F. Khan, Q. Adewale, A. H. Shirazi, t. A. s. D. N. Initiative, *Brain* **2020**, *143* (2), 661.
[94] N. Pai, N. P. Palmer, J. A. Silvester, et al., *PLoS One* **2019**, *14* (10), e0222952.
[95] A. Subramanian, P. Tamayo, V. K. Mootha, et al., *Proceedings of the National Academy of Sciences* **2005**, *102* (43), 15545.

[96] D. N. Reshef, Y. A. Reshef, H. K. Finucane, et al., *Science* **2011**, *334* (6062), 1518.

[97] D. Albanese, M. Filosi, R. Visintainer, et al., *Bioinformatics* **2013**, *29* (3), 407.

[98] K. A. Sharkey, P. L. Beck, D. M. McKay, *Nature Reviews Gastroenterology & Hepatology* **2018**, *15* (12), 765.

[99] P. Brescia, M. Rescigno, *Trends in Molecular Medicine* **2021**, *27* (9), 844.

[100] H. Kadry, B. Noorani, L. Cucullo, *Fluids and Barriers of the CNS* **2020**, *17* (1), 69.


a
Genetic Variant Retrieval
PheGenI
PubMed
Normalization
UCSC liftover
SNPedia
ClinVar
LitVar
Downstream Analyses
Variant collection
Variant annotation
Gene prediction
b
Parkinson's disease retrieved papers
No.: 4411
Crohn's disease retrieved papers
No.: 3137
Parkinson's disease qualified papers
No.: 677
Crohn's disease qualified papers
No.: 318
Parkinson's variants (747)
Parkinson's genes (313)
Crohn's variants (623)
Crohn's genes (319)
c
Literature-derived Variant-to-gene Mapping
Parkinson's & Crohn's
Common-to-common
mapping
Parkinson's specific variants (721)
Parkinson's
specific-to-common
mapping
Common variants (26)
Common genes (31)
Crohn's specific variants (597)
Crohn's
specific-to-common
mapping
Parkinson's specific variants
Common variants
Crohn's specific variants
Common genes corresponding to common variants
Common genes corresponding to specific variants
d
random
observed
PD (313)
CD (319)
31
P-value < 10^-5
Frequency
No. of common genes
e
random
observed
PD (747)
CD (623)
26
P-value < 10^-5
Frequency
No. of common variants
f
Variant functional consequence
intron_variant
missense_variant
no_annotation
upstream_transcript_variant
genic_downstream_transcript_variant
genic_upstream_transcript_variant
synonymous_variant
3_prime_UTR_variant
non_coding_transcript_variant
5_prime_UTR_variant
downstream_transcript_variant
inframe_deletion
frameshift
splice_acceptor_variant
inframe_insertion
stop_gained
splice_donor_variant
initiator_codon_variant
Crohn's disease (613)
Parkinson's disease (679)
g
Crohn's disease (319)
Parkinson's disease (313)
h
Gene functional consequence
protein_coding
lincRNA
miRNA
antisense_lncRNA
intronic_lncRNA
bidirectional_lncRNA
sense_lncRNA
rRNA
tRNA
snoRNA
Crohn's disease (50)
Parkinson's disease (110)


a
Parkinson's disease
Crohn's disease
BP
MF
CC
metabolic process
biological regulation
response to stimulus
multicellular organismal process
localization
cellular component organization
cell communication
developmental process
multi-organism process
cell proliferation
growth
reproduction
protein binding
ion binding
hydrolase activity
nucleic acid binding
transferase activity
nucleotide binding
molecular transducer activity
transporter activity
enzyme regulator activity
lipid binding
chromatin binding
electron transfer activity
structural molecule activity
antioxidant activity
molecular adaptor activity
oxygen binding
carbohydrate binding
translation regulator activity
membrane
endomembrane system
vesicle
membrane-enclosed lumen
protein-containing complex
nucleus
cytosol
extracellular space
cell projection
mitochondrion
endoplasmic reticulum
endosome
Golgi apparatus
cytoskeleton
vacuole
envelope
chromosome
extracellular matrix
ribosome
microbody
lipid droplet
300 200 100 0
0 100 200 300
b
Parkinson's disease
Enrichment in GO_BP
Crohn's disease
positive regulation of NF-kappaB transcription factor activity
positive regulation of NIK/NF-kappaB signaling
positive regulation of nitric-oxide synthase biosynthetic process
response to peptidoglycan
lipopolysaccharide-mediated signaling pathway
defense response to Gram-positive bacterium
positive regulation of I-kappaB kinase/NF-kappaB signaling
detection of bacterium
negative regulation of interleukin-6 production
positive regulation of ERK1 and ERK2 cascade
positive regulation of interleukin-10 production
positive regulation of type 2 immune response
maintenance of gastrointestinal epithelium
positive regulation of peptidyl-serine phosphorylation
positive regulation of interleukin-6 biosynthetic process
positive regulation of tyrosine phosphorylation of STAT protein
positive regulation of activated T cell proliferation
positive regulation of nitric oxide biosynthetic process
negative regulation of tumor necrosis factor production
activation of cysteine-type endopeptidase activity involved in apoptotic process
type I interferon biosynthetic process
nucleotide-binding oligomerization domain containing 2 signaling pathway
interleukin-18 production
cellular response to lipoteichoic acid
positive regulation of interleukin-12 production
positive regulation of granulocyte macrophage colony-stimulating factor production
positive regulation of interleukin-17 production
detection of molecule of bacterial origin
positive regulation of interleukin-1 beta secretion
interleukin-1-mediated signaling pathway
MyD88-dependent toll-like receptor signaling pathway
negative regulation of cytokine production involved in immune response
positive regulation of T cell cytokine production
negative regulation of chemokine production
positive regulation of T-helper 1 type immune response
positive regulation of protein binding
positive regulation of tumor necrosis factor biosynthetic process
chronic inflammatory response
positive regulation of heterotypic cell-cell adhesion
cellular response to amyloid-beta
30 20 10 0
Enrichment ratio
GO terms
0 10 20 30 40
Enrichment ratio
−log10FDR
2 5 8 11
Numbers of genes enriched in the term
c
Enrichment in GO_MF and GO_CC
Parkinson's disease
peptidoglycan binding
amyloid-beta binding
signaling pattern recognition receptor activity
NADH dehydrogenase (ubiquinone) activity
antioxidant activity
receptor antagonist activity
peptide antigen binding
cytokine activity
heme binding
syntaxin-1 binding
ammonium ion binding
oxidoreductase activity, acting on paired donors
NADP binding
solute:proton symporter activity
copper ion binding
interleukin-1 receptor binding
protease binding
FMN binding
vitamin binding
tau protein binding
flavin adenine dinucleotide binding
lipopolysaccharide binding
lipoprotein particle binding
low-density lipoprotein particle receptor binding
Hsp90 protein binding
glutathione transferase activity
MHC class II receptor activity
Hsp70 protein binding
neurotransmitter receptor activity
chaperone binding
growth factor activity
ionotropic glutamate receptor binding
catecholamine binding
electron transfer activity
amino acid binding
phospholipase binding
insulin-like growth factor receptor binding
ubiquitin protein ligase binding
apolipoprotein binding
heparan sulfate proteoglycan binding
steroid binding
chromatin binding
ferrous iron binding
tubulin binding
insulin receptor binding
neurotransmitter:sodium symporter activity
oxidoreductase activity, acting on peroxide as acceptor
SH3 domain binding
aspartic-type peptidase activity
dynein complex binding
chemokine binding
translation initiation factor binding
nuclear receptor transcription coactivator activity
nuclear receptor activity
calmodulin binding
serine-type endopeptidase inhibitor activity
chemokine receptor binding
virus receptor activity
hijacked molecular function
actin binding
Crohn's disease
integral component of lumenal side of endoplasmic reticulum membrane
ER to Golgi transport vesicle membrane
phagocytic vesicle membrane
external side of plasma membrane
MHC class II protein complex
caveola
clathrin-coated endocytic vesicle membrane
plasma membrane receptor complex
recycling endosome membrane
trans-Golgi network membrane
early endosome membrane
secretory granule membrane
lysosomal membrane
late endosome
GABA-ergic synapse
0 10 20 30
Enrichment ratio
GO terms
30 20 10 0
Enrichment ratio
GO terms
Crohn's disease
cytokine activity
peptide antigen binding
CARD domain binding
cytokine receptor activity
cytokine binding
tumor necrosis factor receptor binding
MHC class II receptor activity
CCR chemokine receptor binding
peptidoglycan binding
nuclear receptor activity
signaling pattern recognition receptor activity
steroid hormone receptor activity
RNA polymerase II proximal promoter sequence-specific DNA binding
interleukin-1 receptor binding
kinase regulator activity
protein-containing complex scaffold activity
protein phosphatase binding
retinoid X receptor binding
non-membrane spanning protein tyrosine kinase activity
Parkinson's disease
mitochondrial membrane part
integral component of lumenal side of endoplasmic reticulum membrane
axon part
mitochondrial respiratory chain complex I
clathrin-coated endocytic vesicle membrane
dopaminergic synapse
lysosomal membrane
MHC class II protein complex
inclusion body
perikaryon
early endosome
platelet alpha granule lumen
recycling endosome
dendritic spine
blood microparticle
terminal bouton
ER to Golgi transport vesicle membrane
glutamatergic synapse
lysosomal lumen
integral component of presynaptic membrane
caveola
growth cone
mitochondrial outer membrane
integral component of postsynaptic membrane
postsynaptic density
respiratory chain complex IV
Wnt signalosome
presynaptic cytosol
endoplasmic reticulum lumen
axolemma
apical part of cell
proton-transporting two-sector ATPase complex, proton-transporting domain
endosome lumen
trans-Golgi network membrane
neuromuscular junction
plasma membrane receptor complex
external side of plasma membrane
calyx of Held
mitochondrial intermembrane space
secretory granule membrane
high-density lipoprotein particle
phagocytic cup
axon cytoplasm
juxtaparanode region of axon
tricarboxylic acid cycle enzyme complex
integral component of synaptic vesicle membrane
cytoplasmic stress granule
synaptic cleft
extrinsic component of membrane
ficolin-1-rich granule lumen
basolateral plasma membrane
late endosome membrane
extracellular matrix
hippocampal mossy fiber to CA3 synapse
early phagosome
host cell part
astrocyte projection
−log10FDR
2 4 8 16
Numbers of genes enriched in the term
GO_MF
GO_CC

GO Term	Parkinson's Substantia Nigra			Parkinson's Whole Blood			Crohn's Whole Blood			Crohn's Ileal Mucosa			Crohn's Colonic Mucosa		
	NES	FDR	Enrichment Ratio	NES	FDR	Enrichment Ratio	NES	FDR	Enrichment Ratio	NES	FDR	Enrichment Ratio	NES	FDR	Enrichment Ratio
response to peptidoglycan	1.09	3.54E-01	1.42	1.08	3.69E-01	2.21	1.34	1.13E-01	1.72	1.61	2.02E-02	1.89	1.67	1.32E-02	2.30
peptidoglycan binding	0.72	9.73E-01	0.31	1.20	5.10E-01	1.43	1.55	8.77E-03	1.11	1.96	1.89E-04	1.33	1.88	9.49E-04	1.49
lipopolysaccharide-mediated signaling pathway	1.09	2.08E-01	1.26	1.15	1.12E-04	4.20	1.72	2.35E-04	1.49	2.18	3.23E-06	1.40	2.12	4.20E-06	1.70
lipopolysaccharide binding	0.87	8.27E-01	0.75	1.19	5.39E-02	2.78	1.28	1.21E-01	1.23	1.91	1.83E-04	1.13	1.47	2.90E-02	1.09
defense response to Gram-positive bacterium	1.53	8.47E-03	0.98	1.59	4.83E-03	1.45	1.63	7.01E-04	0.96	1.70	7.29E-04	0.93	2.32	2.12E-06	1.28
detection of bacterium	1.04	3.91E-02	1.09	1.65	5.73E-03	2.03	1.65	4.13E-04	1.80	1.59	2.49E-02	1.41	1.90	5.76E-04	1.48
detection of molecule of bacterial origin	1.12	1.71E-03	1.61	1.38	2.17E-02	1.41	1.68	2.89E-05	1.96	1.89	4.81E-04	1.54	1.57	3.22E-02	1.61
cellular response to amyloid-beta	0.89	1.06E-01	1.46	1.40	8.35E-01	0.57	1.12	4.12E-02	1.38	1.73	2.57E-03	1.05	1.37	2.17E-02	1.41
amyloid-beta binding	0.99	3.78E-04	1.87	0.86	1.01E-01	1.87	1.33	4.81E-02	0.93	1.44	2.22E-02	1.40	1.25	1.76E-03	1.43
tau protein binding	-0.93	2.52E-05	2.44	-1.19	5.56E-01	1.08	-0.90	5.32E-04	1.68	-0.67	9.80E-01	1.17	0.75	6.45E-01	0.96
virus receptor activity	1.26	9.45E-03	1.62	-0.74	1.87E-01	1.65	1.25	4.33E-03	1.42	1.71	7.23E-04	1.30	1.71	5.36E-04	1.44
positive regulation of neuron apoptotic process	1.44	6.58E-02	1.47	0.83	8.40E-02	2.14	1.29	2.59E-03	1.51	1.52	1.50E-02	1.32	1.39	3.39E-02	1.16
positive regulation of Wnt signaling pathway	-1.24	4.71E-04	1.55	0.79	6.06E-01	0.95	1.11	1.01E-03	1.31	1.50	2.29E-03	1.22	1.69	8.62E-06	1.46
neurotransmitter receptor activity	-1.31	4.05E-02	0.98	1.11	9.56E-01	0.42	1.15	1.88E-01	0.25	-1.47	7.09E-03	0.97	-0.96	5.46E-01	0.39
apolipoprotein binding	1.10	2.13E-01	1.54	1.59	2.00E-02	1.43	-0.70	9.05E-01	0.63	1.37	9.77E-02	1.22	0.83	7.23E-01	1.19
neurotransmitter:sodium symporter activity	-0.89	3.84E-04	2.61	1.52	8.24E-01	0.77	1.24	1.82E-01	0.83	-1.43	5.36E-02	0.94	1.05	3.66E-01	1.07
positive regulation of glial cell proliferation	1.04	1.39E-01	1.65	1.10	1.82E-01	2.56	-0.91	1.23E-01	1.42	1.21	2.17E-01	1.29	1.20	2.13E-01	1.07
dopaminergic synapse	-1.65	1.79E-02	1.61	-0.87	6.40E-01	0.96	0.99	4.88E-01	0.62	1.05	3.71E-01	1.16	1.19	2.24E-01	0.59
glutamatergic synapse	-1.82	7.24E-17	1.99	1.15	2.68E-01	1.19	0.84	9.65E-01	1.04	1.09	5.53E-03	1.13	1.09	3.21E-02	1.13
integral component of presynaptic membrane	-1.27	1.03E-04	2.00	0.95	8.07E-01	0.67	-1.21	1.15E-01	0.74	-1.24	5.21E-01	1.01	1.04	3.62E-01	0.76
integral component of postsynaptic membrane	-1.56	1.71E-03	1.61	1.23	9.56E-01	0.42	0.83	8.57E-01	0.60	0.70	4.68E-01	1.02	0.87	8.17E-01	0.69
postsynaptic density	-1.51	2.43E-12	1.85	0.87	2.59E-01	1.20	0.83	9.68E-01	1.02	-0.89	3.91E-02	1.09	-1.11	1.48E-01	1.03
presynaptic cytosol	-1.50	1.12E-01	1.87	1.33	4.01E-01	1.09	-0.75	8.26E-01	0.96	1.03	4.70E-02	1.48	1.17	2.52E-01	1.09
integral component of synaptic vesicle membrane	-1.38	2.04E-04	2.46	0.98	7.60E-01	0.72	1.08	3.31E-01	1.35	0.69	8.88E-01	0.83	1.12	2.63E-01	1.04
synaptic cleft	-1.20	2.69E-04	3.36	0.76	7.92E-01	0.93	0.83	7.15E-01	0.77	1.18	4.70E-02	1.48	0.63	1.40E-01	1.45
hippocampal mossy fiber to CA3 synapse	-1.55	7.46E-03	2.00	1.24	7.60E-01	0.72	1.04	3.99E-01	0.87	0.62	6.10E-02	1.28	-1.14	2.32E-01	0.67
astrocyte projection	-1.09	4.11E-01	1.31	1.30	4.52E-01	1.11	-0.73	8.38E-01	1.12	0.99	3.14E-02	1.57	-1.24	5.28E-02	1.69
GABA-ergic synapse	-2.11	5.55E-07	2.35	1.19	4.92E-01	1.07	0.68	9.88E-01	0.49	-0.76	7.74E-01	0.93	0.88	7.40E-01	0.86



b

	Pathway	Parkinson's Substantia Nigra			Parkinson's Whole Blood			Crohn's Whole Blood			Crohn's Ileal Mucosa			Crohn's Colonic Mucosa		
		NES	FDR	Enrichment Ratio	NES	FDR	Enrichment Ratio	NES	FDR	Enrichment Ratio	NES	FDR	Enrichment Ratio	NES	FDR	Enrichment Ratio
Parkinson's Specific Genetic Pathways	Dopaminergic synapse	-2.15	2.83E-08	1.91	1.20	2.15E-03	1.85	0.64	1.58E-03	1.89	-1.32	1.37E-02	1.68	-1.00	2.19E-03	1.85
	Oxidative phosphorylation	-2.11	4.79E-08	3.06	0.78	2.25E-10	2.96	0.46	1.13E-10	3.03	-1.52	9.77E-04	2.64	-1.66	2.40E-04	2.95
	Drug metabolism - cytochrome P450	0.82	8.24E-01	1.61	0.66	9.24E-02	1.55	1.00	8.15E-02	1.59	-2.72	2.85E-12	2.83	-2.18	3.69E-07	1.55
	Tyrosine metabolism	-1.33	1.38E-05	3.79	0.64	1.97E-05	3.67	1.15	1.54E-05	3.76	0.91	5.02E-07	3.94	-1.40	4.51E-02	3.67
	Metabolism of xenobiotics by cytochrome P450	0.60	9.87E-01	1.62	1.05	7.79E-02	1.56	0.73	6.80E-02	1.60	-2.68	6.58E-12	3.07	-2.09	9.35E-07	1.56
	Synaptic vesicle cycle	-2.61	3.87E-11	2.56	0.54	1.46E-04	2.48	0.71	1.08E-04	2.53	0.84	8.48E-04	2.16	0.74	1.48E-04	2.47
	Ferroptosis	1.37	7.30E-02	0.51	1.12	9.22E-01	0.50	0.83	9.16E-01	0.51	0.98	4.93E-01	0.65	0.94	5.63E-01	0.50
	Tryptophan metabolism	-0.95	8.87E-05	3.25	0.67	1.25E-04	3.15	0.88	9.86E-05	3.22	1.02	2.96E-08	4.01	1.57	2.10E-02	3.14
	Thermogenesis	-1.43	3.70E-07	2.13	-0.72	9.69E-07	2.06	0.45	5.00E-07	2.11	-1.46	4.61E-04	1.83	-1.68	4.45E-06	2.06
	Arginine and proline metabolism	-1.00	7.39E-04	2.68	-1.22	1.01E-03	2.59	0.79	8.15E-04	2.65	1.02	1.16E-03	2.43	0.96	1.02E-03	2.59
	Histidine metabolism	0.79	1.28E-05	4.78	-0.72	1.73E-05	4.62	0.87	1.41E-05	4.73	-1.34	5.80E-05	4.03	-1.02	1.74E-05	4.61
	Ubiquinone and other terpenoid-quinone biosynthesis	0.63	9.00E-01	0.80	-0.70	7.19E-01	1.20	0.79	3.34E-01	0.89	-1.10	3.34E-01	0.81	-0.87	6.52E-01	0.63
	Serotonergic synapse	-1.54	5.78E-03	1.46	0.73	9.73E-02	1.41	0.86	8.34E-02	1.45	-1.35	1.77E-02	1.85	-0.85	9.81E-02	1.41
	Lysosome	-0.80	5.92E-04	1.99	-0.82	2.44E-05	2.23	1.27	6.90E-04	1.97	0.95	7.74E-09	2.62	1.20	8.97E-06	2.31
	Longevity regulating pathway	1.15	3.89E-03	2.01	0.91	5.44E-03	1.94	0.97	4.32E-03	1.99	-1.10	2.01E-02	1.69	-1.04	5.51E-03	1.94
	Prolactin signaling pathway	-1.02	3.48E-01	1.20	0.92	3.83E-01	1.16	1.09	3.59E-01	1.19	1.30	3.93E-01	1.14	1.31	3.84E-01	1.16
	Calcium signaling pathway	-1.46	1.09E-10	2.45	0.80	3.94E-10	2.37	0.54	1.63E-10	2.43	1.28	6.10E-08	2.07	-1.05	4.13E-10	2.37
	Autophagy - animal	-0.84	8.50E-01	0.45	-0.58	9.73E-01	0.58	1.02	9.95E-01	0.44	-0.74	9.83E-01	0.69	0.72	9.78E-01	0.58
	One carbon pool by folate	0.85	7.12E-01	1.05	-0.74	5.99E-01	1.02	1.03	5.86E-01	1.04	0.94	5.40E-01	1.33	1.26	1.75E-01	1.02
	Retrograde endocannabinoid signaling	-1.76	7.59E-05	1.21	1.06	2.86E-01	1.17	0.67	2.55E-01	1.19	-1.35	1.17E-02	1.02	-1.13	1.59E-01	1.17
	Drug metabolism - other enzymes	-0.79	8.74E-01	0.53	0.92	9.62E-01	0.51	1.00	9.56E-01	0.52	-2.18	4.54E-07	0.89	-1.85	8.52E-05	0.51
	VEGF signaling pathway	-0.80	8.21E-01	1.07	-0.98	5.30E-01	1.03	0.62	5.07E-01	1.06	1.46	4.39E-02	0.90	1.43	3.53E-02	1.03
	Arginine biosynthesis	-1.17	1.44E-02	2.87	0.85	1.68E-02	2.77	-1.03	1.51E-02	2.84	0.90	3.11E-02	2.42	1.70	1.05E-02	2.77
	Mineral absorption	1.31	6.64E-06	3.15	-0.81	1.06E-05	3.05	-1.10	7.67E-06	3.12	-2.26	1.31E-06	2.66	-1.58	5.24E-03	3.05
	Glycine, serine and threonine metabolism	-1.35	1.12E-02	2.36	0.47	4.40E-03	2.54	1.01	1.20E-02	2.34	0.97	1.10E-03	2.66	-0.80	4.44E-03	2.54
	Fatty acid degradation	1.00	3.01E-14	5.86	-0.69	6.32E-14	5.67	0.64	3.79E-14	5.80	-1.40	1.26E-13	5.15	-1.76	2.48E-03	5.67
	Porphyrin metabolism	-0.67	1.79E-02	2.20	-0.82	2.18E-02	2.13	1.42	3.15E-02	2.18	-2.27	5.61E-06	1.85	-2.16	4.15E-06	2.12
	Apoptosis	1.02	9.27E-08	2.63	-0.49	1.83E-08	2.69	0.63	1.19E-07	2.60	1.18	2.07E-14	3.19	1.55	3.08E-03	2.69
	Estrogen signaling pathway	0.98	6.36E-02	1.45	1.44	2.82E-03	1.47	0.97	6.90E-02	1.43	1.21	1.48E-01	1.28	1.25	5.00E-02	1.47
	Aminoacyl-tRNA biosynthesis	-1.03	9.89E-01	0.32	-1.57	5.94E-03	0.31	1.51	3.24E-03	0.32	-0.94	6.15E-01	0.40	-1.10	9.91E-01	0.31
	Folate biosynthesis	-0.90	3.20E-02	2.42	1.15	3.69E-02	2.35	0.55	3.35E-02	2.40	-1.47	4.65E-02	2.38	0.88	3.71E-02	2.34
	cAMP signaling pathway	-1.25	1.75E-17	3.09	1.10	9.56E-17	2.99	0.52	2.97E-17	3.06	1.26	8.68E-14	2.60	-0.99	1.02E-16	2.99
	Glycolysis / Gluconeogenesis	-1.27	9.23E-06	2.98	-0.68	1.49E-05	2.88	0.72	1.07E-05	2.95	-1.57	5.21E-03	2.78	0.90	1.51E-05	2.88
	Pyruvate metabolism	-1.41	1.08E-07	4.02	-0.71	1.79E-07	3.89	-0.81	1.26E-07	3.98	-1.62	6.08E-03	3.77	-1.36	1.83E-07	3.89
	Sphingolipid signaling pathway	1.00	5.87E-01	0.97	1.01	5.09E-01	1.03	0.73	6.01E-01	0.96	-0.90	7.66E-01	0.89	1.21	1.41E-01	1.02
	Ovarian steroidogenesis	1.21	2.46E-03	2.47	-0.62	3.25E-03	2.39	1.03	2.68E-03	2.45	-1.21	5.57E-06	3.13	-0.99	3.28E-03	2.39
	Circadian rhythm	0.81	6.85E-02	2.03	0.81	7.80E-02	1.97	-1.08	7.14E-02	2.01	-1.12	1.30E-01	1.71	-1.17	7.83E-02	1.97
	Rap1 signaling pathway	1.07	8.76E-03	1.55	0.80	4.39E-03	1.60	0.75	1.01E-02	1.54	1.14	3.02E-02	1.39	1.18	4.48E-03	1.60
	mTOR signaling pathway	-0.83	8.84E-01	0.75	0.76	9.07E-01	0.72	0.60	8.91E-01	0.74	0.81	8.41E-01	0.63	0.87	7.62E-01	0.72
Common Genetic Pathways	HIF-1 signaling pathway	1.13	4.91E-02	1.54	-0.56	6.67E-02	1.49	1.00	5.65E-02	1.53	1.39	3.40E-02	1.38	1.50	5.40E-03	1.49
	Hematopoietic cell lineage	1.17	4.90E-14	3.93	1.08	1.39E-13	3.80	0.74	6.78E-14	3.89	1.71	4.20E-04	3.40	2.46	6.65E-15	3.79
	Toll-like receptor signaling pathway	-1.09	5.36E-01	1.01	-0.62	5.79E-01	0.98	0.78	5.49E-01	1.00	2.23	6.56E-11	0.94	2.40	3.56E-13	0.98
	TNF signaling pathway	-0.75	1.80E-03	1.97	-0.50	2.70E-03	1.91	1.24	2.05E-03	1.95	2.17	3.44E-10	1.66	2.39	8.26E-13	1.90
	Antigen processing and presentation	1.59	7.53E-03	1.21	1.11	2.34E-01	1.30	-1.57	3.07E-03	1.20	1.10	3.12E-01	1.36	2.32	2.75E-10	1.30
	Intestinal immune network for IgA production	1.06	3.84E-01	1.29	1.33	4.21E-02	1.24	-1.06	2.72E-01	1.27	1.60	1.13E-02	1.08	2.48	9.64E-13	1.24
	NOD-like receptor signaling pathway	1.06	3.40E-01	0.80	0.82	8.15E-01	0.83	1.35	4.46E-03	0.79	1.98	2.80E-09	1.11	2.35	2.01E-15	0.83
	C-type lectin receptor signaling pathway	0.92	6.43E-01	1.41	0.72	1.40E-01	1.37	0.85	1.23E-01	1.40	1.67	1.28E-03	1.28	1.99	7.02E-07	1.37
	Phagosome	0.94	5.91E-01	1.38	0.94	1.08E-01	1.34	1.05	9.13E-02	1.37	1.97	1.53E-08	1.40	2.24	6.16E-12	1.34
	IL-17 signaling pathway	-1.27	9.73E-02	0.78	-0.92	8.30E-01	0.76	0.98	5.66E-01	0.77	2.72	4.07E-25	0.75	2.59	3.31E-17	0.76
	MAPK signaling pathway	1.25	3.08E-02	1.36	0.59	4.74E-02	1.31	0.71	3.54E-02	1.34	1.38	4.68E-03	1.24	1.07	4.82E-02	1.31
	NF-kappa B signaling pathway	1.09	3.62E-02	1.62	-0.60	4.68E-02	1.56	0.83	3.92E-02	1.60	1.97	1.70E-06	1.53	2.34	5.37E-12	1.56
	Cytokine-cytokine receptor interaction	0.97	4.93E-04	1.64	0.87	5.51E-04	1.62	0.89	6.17E-04	1.62	2.32	1.11E-24	1.44	2.36	3.55E-20	1.62
	Th17 cell differentiation	0.96	5.49E-01	0.88	-0.68	7.48E-01	0.85	-0.89	7.23E-01	0.87	1.58	2.14E-03	0.74	2.45	1.10E-14	0.85
	Necroptosis	1.07	3.25E-01	1.39	0.87	9.90E-02	1.34	0.99	8.27E-02	1.37	1.40	1.42E-02	1.28	1.53	2.39E-03	1.34
	Adipocytokine signaling pathway	0.96	5.44E-01	1.22	0.66	3.68E-01	1.18	1.00	3.44E-01	1.21	0.86	7.19E-01	1.03	-0.95	5.73E-01	1.18
	PI3K-Akt signaling pathway	1.47	6.82E-04	1.54	1.13	1.92E-03	1.49	0.68	1.16E-03	1.53	1.50	1.91E-04	1.30	1.55	1.09E-04	1.49
	Osteoclast differentiation	1.47	1.12E-02	0.90	-0.74	7.26E-01	0.87	1.27	4.26E-02	0.89	2.26	7.41E-13	0.97	2.35	9.10E-13	0.87
Crohn's Specific Genetic Pathways	Th1 and Th2 cell differentiation	1.02	3.85E-01	1.03	-0.63	5.59E-01	0.99	-1.21	9.20E-02	1.02	1.14	2.64E-01	0.87	2.30	6.58E-11	0.99
	JAK-STAT signaling pathway	1.07	3.36E-01	1.30	0.90	1.14E-01	1.32	0.76	9.39E-01	1.28	1.83	2.52E-06	1.15	1.96	3.07E-07	1.32
	Cell adhesion molecules	1.19	1.64E-03	1.83	0.97	1.23E-03	1.84	-0.93	1.90E-03	1.81	1.58	8.85E-04	1.60	2.28	3.04E-12	1.84
	Natural killer cell mediated cytotoxicity	-0.73	8.87E-01	0.72	0.88	9.08E-01	0.70	-1.36	2.23E-03	0.71	1.45	1.74E-02	0.61	2.08	2.01E-08	0.70
	T cell receptor signaling pathway	-1.24	1.67E-03	2.02	-0.84	1.03E-03	2.05	-1.24	2.60E-02	2.00	0.69	2.51E-03	1.87	1.73	2.04E-04	2.05
	Cellular senescence	-0.92	2.10E-05	2.16	1.01	4.06E-05	2.09	0.58	2.58E-05	2.13	1.30	2.43E-04	1.87	1.35	1.47E-02	2.08
	Chemokine signaling pathway	-0.93	8.06E-03	1.59	0.80	1.25E-02	1.54	0.97	9.25E-03	1.57	2.10	1.28E-11	1.38	2.34	9.90E-16	1.53
	Wnt signaling pathway	0.91	6.33E-01	0.94	-0.65	2.85E-01	1.16	-0.93	6.49E-01	0.93	1.31	5.04E-02	1.01	0.94	2.87E-01	1.16
	TGF-beta signaling pathway	1.44	2.93E-03	2.01	0.82	4.18E-03	1.95	-0.77	3.28E-03	1.99	1.26	7.99E-03	1.79	-1.09	4.24E-03	1.94
	Cytosolic DNA-sensing pathway	0.78	8.63E-01	0.67	0.72	8.80E-01	0.65	-1.02	8.68E-01	0.66	1.86	1.72E-04	0.56	1.98	1.13E-05	0.64
	RIG-I-like receptor signaling pathway	-1.03	4.13E-01	0.60	-0.80	9.24E-01	0.58	0.74	9.15E-01	0.59	1.56	9.40E-03	0.76	1.53	8.07E-03	0.58
	Adherens junction	0.97	3.45E-02	1.78	0.97	1.19E-03	2.29	0.61	3.69E-02	1.76	0.77	4.89E-03	2.00	0.83	1.21E-03	2.29
	FoxO signaling pathway	0.88	2.74E-03	1.84	0.73	4.16E-03	1.78	0.89	3.12E-03	1.83	0.84	1.10E-02	1.62	1.11	4.22E-03	1.78
	Leukocyte transendothelial migration	1.36	5.04E-02	1.20	1.06	5.31E-02	1.52	0.96	3.00E-01	1.19	1.61	2.10E-03	1.48	1.82	2.29E-05	1.51

a

Permeability Marker	Crohn's IM		Crohn's CM	
	FC/NES	FDR	FC/NES	FDR
MUC1	3.28	3.52E-140	1.24	5.70E-15
ZO-1	-0.21	7.86E-05	-0.38	1.98E-05
ZO-3	-2.01	4.80E-02	-0.50	3.12E-04
occludin	-0.48	2.91E-05	-0.58	1.02E-07
claudin 1	1.74	2.74E-53	1.36	5.52E-11
claudin 2	0.77	6.16E-08	1.26	3.65E-14
claudin 3	-0.39	4.63E-03	-0.43	4.10E-03
claudin 8	-1.64	2.04E-22	-3.15	4.14E-10
JAM3	1.25	1.74E-02	0.37	3.30E-02
E-cadherin	-0.33	2.35E-02	-0.41	2.43E-03
zonulin	2.41	1.45E-15	0.17	8.39E-03
ABCB1	-1.37	1.14E-26	-1.16	1.59E-13
SERPINA1	-1.86	3.22E-01	1.41	7.20E-22
ALPI	-0.87	1.40E-06	-0.28	4.00E-05
LBP	2.09	6.06E-16	0.74	5.03E-03
Wnt signaling	1.31	5.04E-02	0.94	2.87E-01

b



c



d



Parkinson's specific genetic pathways
Common genetic pathways
Significant pathway up-regulation
Crohn's specific genetic pathways
Other important pathways
Significant pathway down-regulation

a

Permeability Marker	Crohn's WB		Parkinson's WB	
	FC/NES	FDR	FC/NES	FDR
ZO-3	-0.58	2.71E-02	-0.12	4.37E-02
E-cadherin	-0.42	1.02E-05	-0.22	5.92E-02
MUC1	0.25	1.70E-03	0.04	4.63E-01
claudin 5	0.88	3.11E-02	-0.12	4.93E-01
ABCB1	-0.65	1.48E-06	0.03	5.39E-01
SERPINA1	0.18	1.32E-04	0.23	3.94E-02
zonulin	1.44	5.78E-07	1.01	6.03E-02
PLEKHA7	-0.44	1.07E-03	0.13	8.78E-01
Wnt signaling	-0.65	2.85E-01	-0.93	6.49E-01

b



c



a

Permeability Marker	Crohn's WB FC	Crohn's WB FDR	Parkinson's WB FC	Parkinson's WB FDR	Parkinson's SN FC	Parkinson's SN FDR
SERPINA1	0.18	1.32E-04	0.23	3.94E-02	-	-
MUC1	0.25	1.70E-03	0.04	7.03E-01	-	-
TLR4	0.63	1.25E-05	-0.02	9.52E-02	-	-
caspase 4	0.31	1.54E-06	0.14	3.17E-01	-	-
caspase 5	0.28	2.91E-07	0.01	6.39E-01	-	-
zonulin	1.44	5.78E-07	1.01	6.03E-02	0.51	2.63E-02
VEGFA	-	-	-	-	0.84	1.50E-02
claudin 1	-	-	-	-	-0.75	7.46E-04
claudin 5	-	-	-	-	0.54	1.73E-02
ZO-3	-	-	-	-	-0.30	1.12E-01
JAM3	-	-	-	-	0.38	4.01E-04

b



c

Gut-blood-brain axis for Parkinson's and Crohn's disease comorbidity